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PREAMBLE 
 
The subject of this dissertation is the work I carried out at AB ANALITICA s.r.l. 
(AB ANALITICA in this writing) in the context of a doctoral program based on 
higher apprenticeship, an innovative form of PhD aiming at reducing the distance 
between academia and business. 
AB ANALITICA has over 20 years of experience in the development of devices 
for molecular diagnostics, their targets ranging from oncology relevant markers to 
markers for thrombophilia and coeliac disease. They also have a panel of devices 
for the detection of infective pathogens. In particular, their catalogue features 
several options for the detection of human papillomavirus (HPV), the etiological 
agent of cervical cancer.  
At the beginning of my PhD, I worked on a project aiming at the enhancement of 
the performance of an already existing device for HPV detection, called 
REALQUALITY RI-HPV STAR. The objective of increasing sensitivity was 
fulfilled. However, doubts on the robustness of the improved prototype emerged 
and the project was abandoned. As the possibility to reach the desired level of 
sensitivity by modifying an already existing device had vanished, I moved to the 
design of  two new assays for HPV detection. The validation tests on the new 
devices proved they performed well and, thus, will be soon commercialized under 
the names: REALQUALITY RQ-HPV HR MULTIPLEX and REALQUALITY 
RQ-HPV HR/LR MULTIPLEX.  
To put into context the whole work it appears necessary to firstly introduce the 
biological target of these devices: in section 1, papillomaviruses are presented 
with a focus on their biology and the strict connection existing between persisting 
infections and cancer, especially that of the cervix. The characteristics of the 
devices I worked on and the precise requirements that had to be satisfied for their 
development are presented in section 2. In section 3, the experiments performed to 
set up the assays and assess their performances are reported. In section 4 methods 
employed throughout the all work are summarized. Discussion on the project 
outcomes and future perspectives follows in section 5. 
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1. INTRODUCTION 
 
1.1. CLASSIFICATION OF  PAPILLOMAVIRUSES 
 
Papillomaviridae is a family of non enveloped viruses with circular double 
stranded DNA genomes. Due to these characteristics, it had originally been 
lumped with the polyomaviriuses in one family, the Papovaviridae. Once 
genomic data became available, it appeared clearly that the two virus groups share 
no major nucleotide or amino acid sequence similarities, and the International 
Committee on the Taxonomy of Viruses (ICTV) officially recognized them as two 
separate families (1).  
The definition of a taxonomic hierarchy below the level of family represented a 
challenge as well. Usually taxonomic criteria used by the ICTV for species 
demarcation are based on multiple data such as, for example, natural host range, 
cell and tissue tropism, pathogenicity and cytopathology, mode of transmission, 
physiochemical and antigenic properties. The characterization of papillomaviruses 
(PVs) and their biological properties, though, has been hampered for a several 
reasons: an adequate tissue culture system (terminally differentiating epithelia) to 
propagate these viruses on a large scale was not available, neither was it possible 
to transmit them to laboratory animals. Moreover, in their natural hosts, these 
viruses do not elicit robust antibody responses, which impaired a classification 
based on “serotype” designations. Therefore, a classification of PVs based 
predominantly on nucleotide sequence similarities represented the only feasible 
alternative and served as the foundation for a nomenclature that was finally 
accepted by ICTV in 2003, despite representing an exception to conventional 
rules (2).  
In the early phases of research on PV taxonomy, large amounts of viral particles 
were isolated from warts and lesions of Epidermodysplasia verruciformis patients. 
The existence of different HPV isolates, generally described as “types”, was 
initially recognized by subjecting the viral DNA to restriction fragment analysis 
and pairwise southern blot hybridization under nonstringent conditions (3). Each 
laboratory started using its own nomenclature to name different types and this was 
12 
 
generating confusion in the field. To assure univocal designation, the participants 
to one of the first workshop on papillomaviruses, held at the University of South 
Alabama College of Medicine in 1978, proposed a uniform nomenclature for the 
PV types already described as well as a scheme for future designation (4). 
According to these criteria, the abbreviation designing a virus should have been 
formed by the first two letters of the English
1
 name of the animal that was the 
natural host of the virus. For human and bovine papillomaviruses, HPV and BPV 
abbreviations, commonly used in literature at the time, were retained. The 
abbreviation had to be followed by a number providing priority to the publication 
date (e.g. HPV1, HPV2, etc.). A criterion to define a new PV type was defined as 
well: any new full length isolate showing less than 50% similarity
2
 to any other 
known PV type. A subtype, i.e. an isolate with more than 50% similarity to 
another PV, would have been designated in alphabetical sequence in lower case 
(e.g. HPV1a, HPV1b, etc.).  
Once PCR and sequencing technologies became available, the criterion for the 
definition of a new PV type was modified to the following: any full-length 
genome showing less than 90% similarity in the L1 sequence
3
 to the closest 
related known PV type. 
The need for a complete taxonomic classification, however, had not been fulfilled 
yet. In 1995 Chan et al. used a stretch of 291 conserved bp of the L1 ORF to 
generate a phylogenetic tree for PVs, which highlighted the existence of five 
“supergroups” (A-E) and several minor “groups” (e.g. A1, A2, etc.) (Fig.1) (6). 
Even though, at the time, the ICTV rejected the groupings proposed by Chan and 
colleagues, that classification was soon accepted and implemented by scientists in 
the field so that, for example, the expression “HPV16 belonging to A9” became 
common.  
In 2003, Fauquet and colleagues (7) proposed a revision to ICTV taxonomic 
guidelines for species demarcation, suggesting taking into account also 
sequencing data. Later that year a group of scientist, comprising Fauquet himself, 
                                                             
1 From 2010 the scientific name of the host species is used (e.g. Felis domesticus PV type 1 is FdPV1) (5). 
2 The degree of similarity should have been investigated preferentially by DNA:DNA hybridization followed 
by S1 nuclease digestion. 
3 L1 sequence is the most conserved sequence in HPV genome. 
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re-proposed a taxonomic classification of PVs based on sequence relatedness. 
Their phylogenetic tree, very similar to that of Chan and colleagues, was 
generated using the L1 sequences of 118 PVs (the 96 HPV types know at the time  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Chan et al. phylogenetic tree of 92 PV types based on a weighted parsimony evaluation of the 291-bp 
L1 segment [from (6)]. 
 
plus 22 other animal PVs). In their proposal, though, the term “supergroup” was 
substituted by “genus” and the term “group” by “species” to align to the 
classification standards of ICTV. They also proposed to use Greek alphabet for 
genus and species (2). These amendments to the commonly used classification 
were favorably welcome by ICTV that finally accepted the proposed taxonomy 
and the deriving nomenclature. The proposal is discussed in details in de Villiers 
et al. (8). According to that taxonomy, different genera share less than 60% 
nucleotide sequence identity in the L1 ORF; species within a genus between 60% 
and 70%; types within a species between 71% and 89%; subtypes between 90% 
and 98%, and variants between 98 and 99%.  
14 
 
The existence of these levels as real natural taxa, and not only as groupings 
established by convention, could also be demonstrated by plotting frequencies 
against pairwise identity percentages obtained from the sequence comparisons of 
the L1 ORF of the same 118 PV types used for generating the phylogenetic tree 
(8). The deriving histogram clearly shows at least three major clusters 
corresponding to genus, species and type taxa (Fig. 2). 
Fig. 2. Frequency distribution of pairwise identity percentages derived from the comparison of the L1 ORFs 
of 118 papillomavirus types [from (8)]. 
 
By now, nearly 200 different HPV types have been isoleted (2) and assigned to a 
species. High throughput sequencing of biological samples, though, revealed that 
there are many more of them. Viruses identified by metagenomic analysis are not 
officially recognized as new types yet, however, a debate on the subject is 
ongoing. In fig. 3 a phylogenetic tree generated using the sequences of 170 HPVs, 
single animal papillomaviruses and new HPVs identified using metagenomic 
sequencing (designated with the prefix “m” followed by a code) is presented. 
Medically relevant HPVs are comprised in the alpha (mucosotropic and 
cutanoetropic HPVs), beta (cutaneotropic HPVs) and gamma (cutaneotropic 
HPVs) genera (8). 
15 
 
 
 
Fig.3. Phylogenetic tree based on the L1 ORF of 170 HPV types, single animal papillomaviruses and newly 
identified human papillomaviruses using metagenomic sequencing [from (2)] 
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1.2. HUMAN PAPILLOMAVIRUSES 
 
1.2.1. STRUCTURE OF THE VIRION 
 
Human papillomaviruses are small, non-enveloped, icosahedral DNA viruses that 
have a diameter of 52–55 nm. The viral particles consist of a single double-
stranded circular DNA molecule of about 8000 bp that is bound to cellular 
histones and contained in a protein capsid composed of 72 pentameric capsomers. 
The capsid is formed from two structural proteins — late 1 (L1, 55 kDa in size; 
80% of total viral protein) and late 2 (L2; 70 kDa) (9). 
 
1.2.2. HPV GENOME AND VIRAL PROTEINS 
 
The genome of all HPV types comprises approximately eight open reading frames 
(ORF), which are transcribed as polycistronic messages from a single DNA 
strand. It can be divided into three functional parts: the early (E) region that 
encodes proteins (E1–E7) necessary for viral replication; the late (L) region that 
encodes the structural proteins (L1–L2) that are required for virion assembly; and 
a largely non-coding part that is referred to as the long control region (LCR) or 
the upstream regulatory region (UUR), which contains cis elements that are 
necessary for the replication and transcription of viral DNA (10) (Fig. 4). The 
early E1 protein possesses ATPase and helicase functions, binds to the origin as 
an hexamer and initiates viral DNA replication. E2 is the main regulator of virial 
gene transcription, binding viral promoters as a dimer. It is also implicated in 
replication as it recruits E1 to the origin. Despite its genomic location and its “E” 
designation, the E4 protein is expressed primarily at later stages. It interacts with 
the keratin cytoskeleton, via a leucine-rich motif at its N-terminus, and disrupts it, 
thanks to an hydrophobic sequence at its C terminus. This compromise the 
structural integrity of infected cells in the upper layers of warts and enable cells to 
rupture and release newly synthesized virus particles into the environment (9, 11). 
E5 is a membrane protein that localizes mainly at the endoplasmatic reticulum 
(ER) and the Golgi apparatus (GA). It can induce cell proliferation and inhibit 
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apostosis, activating grow factor receptors and other protein kinases. It also 
responsible for a mechanism of immune evasion as it interacts with the 16k 
subunit c of vacuolar ATPase, inducing alkalinization of the GA which impairs 
traffic of major histocompatibility complex (MHC) class I to the cell surface (12).    
 
Fig. 4. Schematic presentation of the HPV genome showing the arrangement of the early genes (E), the 
capsid genes (L1 and L2) and the upstream regulatory region (URR) [Modified from (13)].  
 
The best known property of the E6 protein is the ability to bind and degrade the 
tumour-suppressor protein p53 through the recruitment of the protein ligase, E6-
associated protein (E6-AP). This results in inhibition of the transcriptional activity 
of p53 and the abrogation of p53-induced apoptosis. In addition, E6 binds to 
numerous other cellular proteins that can be divided into four broad classes: 
transcriptional co-activators, proteins involved in cell polarity and motility, 
tumour suppressors and inducers of apoptosis, and DNA replication and repair 
factors. E6 also induces the expression and activation of the telomerase (9). As E5 
and E6, E7 induces unscheduled cell proliferation; it inactivates negative 
regulators of the cell cycle and tumour suppressors, primarily the retinoblastoma 
protein (pRb)  (9). Both E6 and E7 expression is negatively regulated by E2 (11). 
L1 and L2 are the major and minor viral structural proteins respectively. They 
assemble in capsomers and capsids (9, 11). 
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1.2.3. LIFE CYCLE IN PRODUCTIVE INFECTION 
 
HPVs establish productive infections only within stratified epithelia of the skin, 
the anogenital tract and the oral cavity. The viral life cycle is linked to the 
differentiation of the infected epithelial cells (Fig. 5). Virions penetrate the 
epithelium through microabrasions and infect epithelial stem cells that are located  
 
in the basal epithelial cell layer. In these cells and in their progeny, known as 
transit amplifying cells, HPVs replicate their DNA episomally, using two virus-
encoded non-structural proteins, E1 and E2, and the cellular DNA-replication 
machinery. Expression of the viral E5, E6 and E7 non-structural proteins delays 
cell-cycle arrest and differentiation, which is normally observed as epithelial cells 
move up from the basement membrane to become mature keratinocytes. This 
Fig. 5. Daughter cells of epithelial stem cells divide along the basement membrane and then mature 
vertically through the epithelium without further division (right side). After introduction of HPV into 
stem cells in the basal layer of the epithelium, expression of viral non-structural proteins occurs. Under 
the regulation of these proteins, the dividing-cell population expands vertically and epithelial cell 
differentiation is delayed and is less complete. Viral proteins are expressed sequentially with 
differentiation as shown, and mature virions are produced only in the most superficial layers of the 
epithelium. Intraepithelial antigen-presenting cells (APCs) are depleted in the HPV-infected epithelium 
[from (14)]. 
19 
 
delay of cell-cycle arrest allows further viral episome replication using the host 
DNA-replication machinery in suprabasal epithelial cells, and produces the 
thickening of the skin (or wart) characteristic of some papillomavirus infections. 
When the differentiation of replicating epithelial cells to non-replicating mature 
keratinocytes eventually occurs, virus-encoded structural proteins, L1 and L2, are 
assembled in the cell nucleus to form mature virions. These are then released into 
the environment, taking advantage of the disintegration of epithelial cells 
occurring as a consequence of their natural turn-over at the superficial layers (14). 
 
1.2.4. BENIGN MANIFESTATIONS 
 
Human papillomaviruses can affect any area on the skin and mucous membranes. 
Infections with different strains are linked to a variety of skin manifestations 
ranging from common warts to malignancies (malignant manifestation are 
discussed in section 1.3 and 1.4). The current classification system for HPV, 
based on similarities in genomic sequences, generally correlates with the three 
clinical categories applied to HPV infections: 1) mucosal/anogenital, 2) 
cutaneous, and 3) linked to Epidermodysplasia verruciformis. 
The main benign manifestations of mucosal/anogenital warts are cauliflower-like 
condylomata accuminata, which usually involve moist surfaces, and keratotic and 
smooth papular warts, generally found on dry surfaces. They are often 
asymptomatic, but occasionally may cause itching, bleeding after intercourse, 
urinary obstruction, burning, and pain. The majority of clinically manifest 
anogenital warts are caused by HPV genotypes 6 or 11.  
The most commonly seen cutaneous HPV induced lesion is the common wart or 
verruca vulgaris, which can occur anywhere on the skin surface. It is usually 
caused by HPV types 1, 2, 4, 27, and 57. 
Epidermodysplasia verruciformis is a rare hereditary skin disorder characterized 
by abnormal susceptibility to human papillomavirus.
 
The uncontrolled HPV 
infection results in the growth of numerous scaly papules, particularly on hands 
and feet, but also on head and neck. Lesions in Epidermodysplasia verruciformis 
patients usually contain HPV types 5 or 8 (15).  
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1.3. HUMAN PAPILLOMAVIRUS AND CANCER 
 
1.3.1. A BRIEF HISTORICAL ACCOUNT 
 
In 1842 an Italian physician, Rigoni-Stern, analyzed death certificates of women 
in Verona during the period 1760–1839 and observed a high frequency of cervical 
cancer in married women, widows and sex workers, but their rare occurrence in 
virgins and nuns (16). He concluded that the development of this type of cancer 
should be related to sexual contacts. The rapid development of bacteriology in the 
second part of the 19th century resulted in early attempts to link cervical cancer to 
sexually transmitted infectious events, without reproducible data until the end of 
the 1960s. At this time, first reports appeared incriminating Herpes simplex type 2 
as the etiological agent of cervical cancer (17). Although, initially, a number of 
confirmatory data have been published, a large scale prospective study performed 
in former Czechoslovakia failed to confirm these results (18). In the 1970s a 
German virologist, Harald zur Hausen, initiated a series of studies on the possible 
role of human papillomaviruses in cervical cancer (19, 20). Eventually, his 
hypothesis was confirmed, both biologically and epidemiologically (21, 22). In 
2008, zur Hausen received the Nobel Prize in Physiology or Medicine for his 
discovery (23). Investigation on the carcinogenic potential of human 
papillomaviruses, however, were not relegated to the cervix. Even though with 
less striking results, the causal link between HPV and cancers affecting other 
districts was also confirmed (24, 25). 
 
1.3.2. EPIDEMIOLOGICAL EVIDENCE FOR THE CAUSAL LINK 
BETWEEN HPV AND CERVICAL CANCER 
 
In 1995 the International Agency for Research on Cancer (IARC) assembled a  
large series of cases of invasive cervical cancer investigated with a standard 
protocol. About 1000 women with histologically verified invasive cervical cancer 
were recruited from 22 countries around the world. Frozen biopsies from the 
tumors were analyzed in a central laboratory for the detection of HPV-DNA, 
using strict control for the presence of malignant cells in sections adjacent to the 
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sections used for PCR-based assays. After reanalysis of the initially HPV-negative 
cases, HPV-DNA was detected in 99.7% of the tumors, leading to the conclusion 
that HPV is a necessary cause of cervical cancer (26).  
 
1.3.3. EPIDEMIOLOGICAL EVIDENCE FOR THE CAUSAL LINK 
BETWEEN HPV AND OTHER ANOGENITAL CANCERS 
 
The number of studies on the role of HPV in other genital cancers is limited, and 
in most, the search for HPV-DNA has been done for a few HPV types and in 
fixed tissue. The available epidemiological studies indicate that cancers of the 
vagina and of the anus resemble cancer of the cervix with respect to the role of 
HPV. In both, HPV-DNA is detected in the great majority of tumors and their 
precursor lesions. 64-91 % of vaginal cancers and 82-100 % of VAIN-3 (VAginal 
Intraepithelial Neoplasia, grade 3) lesions are HPV-DNA positive. In anal 
cancers, HPV-DNA is detected in 88–94 %. Also cancers of the vulva and of the 
penis have been associated to HPV. The majority (60–90%) of tumors diagnosed 
in young individuals are positive for HPV and their pre-neoplastic lesions are also 
strongly associated with HPV. In older subjects, the tumors are rarely (less than 
10%) associated with HPV (10). 
 
1.3.4. EPIDEMIOLOGICAL EVIDENCE FOR THE CAUSAL LINK 
BETWEEN HPV AND NON-ANOGENITAL CANCERS 
 
HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) 
A recent metanalysis of thirty-nine publications reporting on the prevalence of 
HPV infection in head and neck cancers in European populations produced the 
following results: the pooled prevalence of HPV, as determined by the presence of 
viral DNA, in 3,649 head and neck cancers patients was 40.0%. Estimates by type 
of cancer indicated that the prevalence of HPV infections was highest in tonsillar 
cancer (66.4%). The systematic review also identified two eligible studies 
reporting on cancers of Waldeyer’s ring (a broader anatomical category including 
various tonsillar and tonsil-like tissues), the pooled prevalence of HPV for this 
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group was estimated to be 32.9%. By contrast, HPV prevalence estimates were 
lowest for pharyngeal cancer (15.3%) and tongue cancer (25.7%) (27) (Fig.6).  
 
 
 
Fig. 6. Graphical presentation of the prevalence of HPV in HNSCC by cancer site [from (27)]. 
 
NON-MELANOMA SKIN CANCER (NMSC) 
Apart from genital types, the HPV family includes many cutaneous types that 
belong to the so-called Epidermodysplasia verruciformis (EV)-HPV types. These 
types are potentially involved in the development of non-melanoma skin cancer 
(NMSC), which includes SCC and basal cell carcinoma. HPV-DNA has been 
identified in a substantial proportion (30–50%) of NMSCs in immunocompetent 
populations; this proportion increases up to 90% in immunosuppressed organ 
transplant recipients (10). 
 
OCULAR SURFACE SQUAMOUS NEOPLASIA (OSSN) 
The relationship between human papillomavirus and OSSN is rather controversial 
with variable results. The prevalence of HPV in OSSN ranges from 0% to 100% 
depending on geographical region. Most African studies report prevalence of 75–
85%. On average, considering studies from different regions of the world, 33.8% 
of OSSN lesions are HPV positive. There may be a true geographical variation in 
the prevalence of HPV in OSSN (28). 
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1.4. CERVICAL CANCER 
 
1.4.1. INCIDENCE AND MORTALITY 
 
Cervical cancer is the fourth most common cancer in women worldwide (Fig. 7) 
and the second in less developed countries (Fig.8) (29). Screening programs, 
where available, have helped to reduce the associated mortality considerably.  
 
 
 
Fig. 7. Incidence (blue bars) and mortality (red bars) for the ten most common cancers in males and females 
in the world [from (29)]. 
 
 
 
Fig. 8. Incidence (blue bars) and mortality (red bars) for the ten most common cancers in males and females 
in less developed countries [from (29)]. 
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1.4.2. HIGH RISK HPV TYPES 
 
Cervical cancer is one of the few human cancers to be entirely attributable to 
infection with a virus, the human papillomavirus. Not all HPVs,  however, are 
able to induce cervical cancer. Nearly 200 different types of HPV have been 
identified so far; only 40 (all belonging to the alpha genus), though, are able to 
infect the mucosal epithelium of the cervix. Of these, less than twenty have been 
actually correlated to cervical cancer development. There is no univocal 
agreement on which are the HPV genotypes capable of inducing cervical cancer, 
generally called high risk (HR) HPV types. In Table 1, a classification of 62 HPV 
genotypes, based on the risk of inducing cervical cancer, according to four 
different sources (30-33), is provided. Twelve HPV types are unanimously 
recognized as high risk types by all sources: HPV 16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58 and 59.  
 
GENOTYPE 
Munoz et al. 
2003 
IARC 2012 
Sorbo et al. 
2010 
Cuschieri et 
al.2011 
HPV 3   Low risk  
HPV 6 Low risk Low risk Low risk Low risk 
HPV 10   Low risk  
HPV 11 Low risk Low risk Low risk Low risk 
HPV 13   Low risk  
HPV 16 High risk High risk High risk High risk 
HPV 18 High risk High risk High risk High risk 
HPV 26 
Probable High 
risk 
Possible High 
risk 
Probable High 
risk 
Probable High 
risk 
HPV 28   Low risk  
HPV 29   Low risk  
HPV 30  
Possible High 
risk 
Probable High 
risk 
 
HPV 31 High risk High risk High risk High risk 
HPV 32   Low risk  
HPV 33 High risk High risk High risk High risk 
HPV 34  
Possible High 
risk 
High risk  
HPV 35 High risk High risk 
Probable High 
risk 
High risk 
HPV 39 High risk High risk High risk High risk 
HPV 40 Low risk  Low risk Low risk 
HPV 41   
Probable High 
risk 
 
HPV 42 Low risk  Low risk Low risk 
HPV 43 Low risk  Low risk  
HPV 44 Low risk  Low risk  
HPV 45 High risk High risk High risk High risk 
HPV 51 High risk High risk 
Probable High 
risk 
High risk 
HPV 52 High risk High risk 
Probable High 
risk 
High risk 
HPV 53 
Probable High 
risk 
Possible High 
risk 
Probable High 
risk 
Probable High 
risk 
HPV 54 Low risk  Low risk Low risk 
HPV 55   Low risk Low risk 
HPV 56 High risk High risk High risk High risk 
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GENOTYPE 
Munoz et al. 
2003 
IARC 2012 
Sorbo et al. 
2010 
Cuschieri et 
al.2011 
HPV 58 High risk High risk 
Probable High 
risk 
High risk 
HPV 59 High risk High risk High risk High risk 
HPV 60   
Probable High 
risk 
 
HPV 61 Low risk  Low risk Low risk 
HPV 62   Low risk Low risk 
HPV 64   High risk 
Probable High 
risk 
HPV 66 
Probable High 
risk 
Possible High 
risk 
Probable High 
risk 
Probable High 
risk 
HPV 67  
Possible High 
risk 
High risk 
Probable High 
risk 
HPV 68 High risk 
Probable High 
risk 
High risk High risk 
HPV 69  
Possible High 
risk 
Probable High 
risk 
Probable High 
risk 
HPV 70 Low risk 
Possible High 
risk 
Probable High 
risk 
Probable High 
risk 
HPV 71   Low risk Low risk 
HPV 72 Low risk  Low risk Low risk 
HPV 73 High risk 
Possible High 
risk 
High risk 
Probable High 
risk 
HPV 74   Low risk  
HPV 78   Low risk  
HPV 81 Low risk  Low risk Low risk 
HPV 82 High risk 
Possible High 
risk 
High risk 
Probable High 
risk 
HPV 83   Low risk Low risk 
HPV 84   Low risk Low risk 
HPV 85  
Possible High 
risk 
High risk 
Probable High 
risk 
HPV 86   Low risk  
HPV 87   Low risk  
HPV 89 Low risk  Low risk  
HPV 90   Low risk  
HPV 91   Low risk  
HPV 92   
Probable High 
risk 
 
HPV 94   Low risk  
HPV 96   
Probable High 
risk 
 
HPV 97  
Possible High 
risk 
High risk  
HPV 98   
Probable High 
risk 
 
HPV 99   
Probable High 
risk 
 
HPV 100   
Probable High 
risk 
 
 
Table 1. Classification of 62 HPV genotypes, based on the risk of inducing cancer, according to four different 
sources (Munoz et al. 2003 (30); IARC 2012 (31); Sorbo et al. 2010 (32); Cuschieri et al. 2011 (33)). 
 
In 2009 the World Health Organization (WHO) released a manual for laboratories 
that perform HPV genotyping. In this manual, it is recommended that genotyping 
assays should “detect, at a minimum, the fourteen most common high risk HPV 
types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) and the two low 
risk (LR) HPV types targeted by a current HPV vaccine (6 and 11)” (34). From 
this instructions, it is possible to infer that the WHO regards as high risk types 
also HPV 66 and HPV 68.  
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Independently from the total number of high risk genotype considered as such, the 
major role played by two HPV types, HPV 16 and 18, in cervical cancer 
development cannot be questioned. These two genotypes, together, are 
responsible for the 70% of all cervical cancers (Fig. 9) (35). 
 
 
 
Fig. 9. Relative contribution of HPV 16/18/31/33/45/52/58 in cervical cancer. “SCC”: Squamous cell 
carcinoma; “ADC”: Adenocarcinoma; “ADSCC”: Adenosquamous cell carcinoma; “Other”: Includes 
undifferentiated, neuroendocrine, basal adenoid and cystic adenoid carcinomas [Modified from (35)]. 
 
1.4.3. PATHOGENESIS: CARCINOGENIC MECHANISM OF HIGH RISK 
HPV TYPES 
 
One of the key events of HPV-induced carcinogenesis, and a prerogative of high 
risk types (36), is viral genome integration into a host chromosome. HPV genome 
integration often occurs near common fragile sites of the human genome (37), but 
there are no apparent hot spots for integration and no evidence for insertional 
mutagenesis (38). Integration follows a more specific pattern with respect to the 
HPV genome. Expression of the viral E6 and E7 genes is consistently maintained, 
whereas other portions of the viral DNA are deleted or their expression is 
disturbed. Loss of expression of the HPV E2 transcriptional repressor is 
significant, as it results in upregulated HPV E6 and E7 expression. There is also 
evidence for increased E6/E7 mRNA stability after integration (39). Cells that 
express E6/E7 from integrated HPV sequences have a selective growth advantage 
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over cells with episomal HPV genomes (40). The concept that loss of E2 repressor 
function may be critical for malignant progression is supported by experiments 
showing that re-expression of E2 in cervical cancer cell lines causes growth 
suppression. These experiments clearly demonstrate that continued E6/E7 
expression in cervical cancers is necessary for the maintenance of the transformed 
phenotype (41). 
E7 proteins interact with the retinoblastoma tumor suppressor protein pRB and 
others “pocket proteins”, such as p107 and p130, through a conserved LXCXE 
sequence at its N-terminus. Pocket proteins regulate the activities of the 
transcription factors of E2F family that control multiple cell cycle transitions as 
well as other cellular activities (42). High risk HPV E7 proteins interact with  
pocket proteins more efficiently than E7 proteins encoded by low-risk mucosal 
HPVs (43). Moreover, they have the unique ability to destabilize pocket proteins 
through a proteasome-dependent mechanism (44). In addition, E7 has other 
cellular targets that are relevant to cellular transformation, for example, it can 
override the growth-inhibitory activities of cyclin-dependent kinase inhibitors, 
such as p21
CIP1
 (45) and p27
KIP1
 (46). 
Induction of unscheduled proliferation in cells that presumably lack 
environmental mitogen stimulation results in conflicting growth signals. This 
situation, usually, triggers a cellular defense mechanism, the “trophic sentinel 
response”, that eliminates such deviant cells from the proliferative pool through 
cell type-specific abortive processes, including cell death, differentiation, and 
senescence. This was originally discovered in transgenic mouse models in which 
E7 expression caused aberrant proliferation, which, ultimately, resulted in cell 
death. This process was found to be p53 dependent (47). E6 proteins eliminate the 
trophic sentinel response triggered by E7 expression, through inactivation of p53. 
E6 do not directly associate with p53, but form a complex with the cellular E6-AP 
protein. E6-AP is the founding member of the homology to E6 C terminus 
(HECT) family of E3 ubiquitin ligases. E6 proteins recruits E6-AP to induce 
ubiquitination and rapid proteasomal degradation of p53 (48). High risk HPV E6 
proteins degrade p53 more effectively than E6 proteins encoded by low risk types. 
These proteins also have some unique structural features such as, for example, a 
PDZ binding motif (PBM) on the extreme C-terminus (Fig. 10). Among the 
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cellular PDZ domain-containing targets of E6 are Discs Large (DLG1) and 
Scribble, both component of the cell polarity control machinery. These two 
proteins are compelling candidates for a role in HPV-induced malignancy, with 
loss of expression or mis-localization being a common occurrence in many tumor 
types (49). Finally E6 induces the expression of the telomerase catalytic subunit 
hTERT which causes life span extension and facilitates immortalization. In Fig. 
11 the main steps required for HPV induced carcinogenesis are summarized (50). 
 
 
 
Fig. 10. Sequence alignments of the C-terminal PBM-containing region (last four amino acids) of E6 
oncoproteins derived from 13 high risk HPV types. Conserved residues are in red and blue. The PBM is not 
present in the low risk types HPV 6 and 11. Shown on right is the consensus sequence of a class I PBM 
[Modified from (49)]. 
 
 
 
 
Fig. 11. Schematic outline of the critical steps of 
HPV-induced carcinogenesis: inactivation of pRB 
and p53 tumor suppressor pathways, and 
expression of telomerase catalytic subunit hTERT 
[From (50)]. 
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1.4.4. PATHOGENESIS: PROGRESSION FROM PRECANCEROUS 
LESIONS TO CANCER 
 
The cervix is the lower fibromuscular portion of the uterus. Ectocervix is the most 
readily visible portion of the cervix; endocervix is largely invisible and lies 
proximal to the external os (Fig. 12).  Ectocervix  is  covered by  a  pink  stratified                                            
 
 
 
Fig. 12 Cartoon representing the female reproductive system 
[From (51)]. 
 
 
 
squamous epithelium, consisting of multiple layers of cells, whereas a reddish 
columnar epithelium consisting of a single layer of cells lines the endocervix. 
Upon entering puberty, due to hormonal influence, and during pregnancy, the 
columnar epithelium extends outwards over the ectocervix. Eventually the 
exposed columnar epithelium can undergo physiological metaplasia and revert to 
tougher metaplastic squamous epithelium. This zone of unstable epithelium is 
called the transformation zone and is particularly vulnerable. Generally, HPV 
virions penetrate the epithelium of the transformation zone through 
microabrasions and infect epithelial stem cells that are located in the basal 
epithelial cell layer. Infection with all mucosal HPV types, when persistent, can 
lead to the development of epithelial lesions. Only high risk HPV types, though, 
induce precancerous and cancerous lesions. According to the 2001 Bethesda 
system (52), when analyzed through cytology, epithelial lesions can be 
categorized, from less to more severe, as described in table 2: 
 
BETHESDA SYSTEM  FEATURE 
ASCUS (Atipical Squamous Cell of Undetermined Significance) Atypia 
ASCH (Atipical Squamous Cell cannot exclude HSIL) Atypia 
LSIL (Low grade Squamous Intraepithelial Lesion) Mild dysplasia and dyskaryosis 
HSIL (High grade Squamous Intraepithelial Lesion) 
Moderate to severe dysplasia 
and dyskaryosis 
 
Table 2. The  Bethesda system. 
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Histological specimens, such as punch biopsy or excision specimen, are 
categorized according to the CIN (Cervical Intraepithelial Neoplasia) grading 
system as described in table 3 (53): 
 
CIN GRADING SYTEM FEATURE 
CIN 1  
(Cervical Intraepithelial Neoplasia, grade 1) 
 
Good maturation with minimal nuclear 
abnormalities and few mitotic figures. 
Undifferentiated cells are confined to the 
deeper layers (lower third) of the epithelium. 
Mitotic figures are present, but not very 
numerous. Cytopathic changes due to HPV 
infection may be observed in the full thickness 
of the epithelium. 
 
CIN 2  
(Cervical Intraepithelial Neoplasia, grade 2) 
 
Dysplastic cellular changes mostly restricted to 
the lower half or the lower two-thirds of the 
epithelium, with more marked nuclear 
abnormalities than in CIN 1. Mitotic figures 
may be seen throughout the lower half of the 
epithelium 
 
CIN 3  
(Cervical Intraepithelial Neoplasia, grade 3) 
 
Differentiation and stratification may be 
totally absent or present only in the superficial 
quarter of the epithelium with numerous 
mitotic figures. Nuclear abnormalities extend 
throughout the thickness of the epithelium.  
 
 
Table 3. The CIN grading system. 
 
The LSIL category of the Bethesda systems corresponds to CIN 1 in the CIN 
grading system, whereas the HSIL category corresponds to CIN 2-3. Only 
HSIL/CIN 2-3 lesions are considered precancerous lesions. 
 During cancer progression, the pattern of viral gene expression changes. In CIN 
1, the order of events is generally similar to that seen in productive lesions (see 
paragraph 1.2.3). In CIN 2 and CIN 3, however, the onset of late events is 
retarded, and, although the order of events remains the same, the production of 
infectious virions becomes restricted to small areas close to the epithelial surface. 
Integration of HPV sequences into the host cell genome  accompanies these 
changes leading to the loss of E1 and E2 replication proteins and further 
upregulation of the expression of E6 and E7. In cervical cancer, the productive 
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stages of the virus life cycle are no longer supported and viral episomes are 
usually lost (Fig. 13) (54).  
 
Fig. 13. Cartoon showing viral gene expression changes during progression from LSIL / CIN 1 to cervical 
cancer (CaCx) [From (54)]. 
 
It is important to state, though, that this process requires a long time to reach 
completion (~10 years) and is not unidirectional. Most low and high grade lesions 
regress spontaneously to normal epithelium. A comprehensive review of the 
literature highlighted that regression to normal epithelium occurs in nearly 60% of 
CIN 1 patients, whereas persistence, progression to CIN 3 and progression to 
invasion occur in around 30%, 10% and 1% of patients respectively. The 
corresponding approximations for CIN 2 are 40%, 40%, 20%, and 5%. Finally, 
CIN 3 regresses in 33% of cases and progresses to invasive cancer in about 12% 
of cases. It is evident from the above figures that the probability for an atypical 
epithelium to become invasive increases with the severity of the atypia, but does 
not occur in every case. Even the higher degrees of atypia regress in a significant 
proportion of cases (55). 
 
1.4.5. CERVICAL CANCER PREVENTION: SCREENING PROGRAMS 
 
Organized, population-based screening programs, were available, have 
successfully decreased cervical cancer incidence and mortality. This reduction is 
due to 1) an increase in the detection of invasive cancer at early stages, when the 
5-year survival rate is higher than 90%; and 2) the detection and treatment of 
preinvasive lesions, which reduces the overall incidence of invasive cancer.  
The Papanicolaou test (Pap-test) is traditionally employed for cervical cancer 
screening. This test is performed by opening the vaginal canal with a speculum 
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and collecting cells from the external os and the endocervix with a brush or a 
spatula. Collected cells can, then, be smeared directly on a microscope glass or be 
dispersed in a preservative medium for liquid based cytology (LBC). In case LBC 
is to be performed, the sample is sent to the laboratory where it is spun and treated 
to remove obscuring material, such as mucus or blood. Then, a thin layer of cells 
is deposited onto a slide. The slide is finally examined in the usual way under the 
microscope by a cytologist. The sample is categorized according to the Bethesda 
system (see paragraph 1.4.3). In case no anomalies are observed, the woman is 
referred to a normal screening schedule, which means she will be invited to repeat 
the Pap-test after three years. American (56) and European (57, 58) screening 
guidelines provide gynecologist with proper management algorithms for all the 
other possible cytological outcome (ASCUS, ASCH, LSIL, HSIL).  Without 
going into details, ASCH and HSIL positive patients are always referred to 
colposcopy. LSIL positive patients are referred to colposcopy according to 
American guideline, whereas both colposcopy and repeating the Pap-test are 
acceptable strategies according to European guidelines. For ASCUS positive 
patients, three options are offered by both guidelines: 1) high risk HPV test triage, 
2) Pap-test repetition or 3) direct colposcopy.  
Beside its use in triage of women with equivocal cytological results, HPV testing 
is employed in the follow-up of women treated for CIN to predict success or 
failure of treatment. Furthermore, in recent years, it has been proposed as a tool 
for primary screening, alone or in combination with cytology (co-testing). 
American screening guidelines already recommend HPV testing, in the form of 
co-testing, for women older than 30 years as a preferable alternative to cytology 
alone. For co-testing, the recommended screening interval, in case of negative 
results, is five year instead of three. European guidelines have not defined a 
procedure for HPV testing implementation in primary screening settings yet. 
However, pilot studies in EU countries have been encouraged. Results from this 
studies have provided national governments with sufficient data to define their 
own screening strategies until a unifying European strategy is released. 
In table 4, is a summary of the recommendations on the use of HPV test as a 
primary screening tool extracted from five different documents (59). One of these 
documents corresponds to the above mentioned “American guidelines”, which is a 
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multi-societal document compiled by members of the ACS (American Cancer 
Society), the ASCCP (American Society for Colposcopy and Cervical Pathology) 
and the ASCPS (American Society for Clinical Pathology Screening). In USA 
other guidelines have been released by the USPSTF (U.S. Preventive Service 
Task Force) and their content is reported in table 4 as well. The other three 
reported documents are 1) the recommendations of the Canadian Task Force on 
Preventive Health Care, 2) the Italian Healt Technology Assessment (HTA) report 
and 3) the Dutch Health Council recommendations. Only the Canadian document 
excludes the possibility to employ HPV testing in primary screening. USA 
guidelines recommend its use in the form of co-testing and European documents 
suggest to use HPV testing for primary screening and cervical cytology only for 
triage of HPV positive patients. 
 
  
Table 4. Summary of the recommendations on the use of HPV testing as a primary screening tool extracted 
from five different documents (USPSTF guidelines; ACS/ASCCP/ASCP guidelines; Canadian Task Force on 
Preventive Health Care recommendations; Italian HTA report; Duch Health Council recommendations). a) 
Both cytology and HPV test performed simultaneously as primary screening test; b) Cytology performed 
sequentially only in case of HPV positive results; c) Non-management for HPV negative L-SIL was reported 
on the multi-societal guidelines in 2012. According to the recommendation by the ASCCP published in 2013, 
these women would be referred to 1-year control with HPV testing and cytology [Modified from (59)]. 
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1.4.6. CERVICAL CANCER PREVENTION: VACCINATION 
 
Vaccination programs against HPV are being widely implemented, with young 
adolescent girls being the primary target group for most programs. Two 
prophylactic vaccines are now available: bivalent (bHPV) vaccine targets the two 
HPV types associated to the highest risks of developing cervical cancer (i.e. HPV 
16 and 18); quadrivalent (qHPV) vaccine targets HPV 16 and 18 together with the 
two most common genital low risk HPV types, both responsible for condilomata 
(benign warts) in the genital district (i.e. HPV 6 and 11). Both vaccines continue 
to be immunogenic and well tolerated up to 9 years following vaccination. All 
randomized controlled clinical trials for the bHPV and the qHPV vaccines provide 
evidence of an excellent safety profile (60).  
 
1.4.7. HPV MOLECULAR DETECTION  
 
At the beginning of the HPV molecular detection era, only cumbersome methods, 
like Southern Blot and in situ hybridization, existed. Nowadays, instead, multiple 
different technologies, easier to perform and amenable to automation, are 
available. As previously discussed (see paragraph 1.4.4) HPV detection is 
eventually being implemented also in the context of screening settings (first level 
testing), alone or in combination with conventional cytology. In such a context 
genotyping information are not required, provided that the test is specific for high 
risk genotypes. Genotyping tests are generally used in second level analyses (e.g. 
follow-up of women with abnormal screening results who are negative at 
colposcopy/biopsy, follow-up of women after CIN treatment, etc.). 
 Ideally a screening test should be able to identify all CIN 2+ (CIN 2, CIN 3 and 
cancer) patients. As high risk HPV DNA can be present also in low grade lesions, 
the analytical sensitivity of a screening tests based on HPV DNA detection should 
not be excessively high, in order to avoid referral to colposcopy or further 
examination when not needed. The sensitivity of genotyping tests (second level 
analysis), instead, has to be as high as possible (for details on the sensitivity 
requirements for an HPV genotyping test see paragraph. 2.1). 
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Tests generally employed in clinical settings target HPV DNA; however, assays 
for the detection of HPV RNA and proteins have been developed as well. 
 
DNA DETECTION METHODS 
DNA detection methods generally rely either on signal amplification technologies 
or on target amplification technologies (i.e. PCR). 
Among the first group of assays, the most wildly used test is the digene high risk 
HPV HC2 DNA Test (QIAGEN; HC2 in this writing). This is a non-radioactive 
signal amplification method based on the hybridization of the target HPV DNA to 
labeled RNA probes in solution. This test detects 13 HR-HPV types (HPV 16, 18, 
31, 33, 35, 39, 45, 51, 52, 56, 58,59 and 68), providing no information on the 
specific genotype present in the sample. It was the first device to receive FDA 
approval and is frequently used in primary screening. 
As for PCR assays, some of them employ degenerated or consensus primers, such 
as MY09/11, GP 5+/6+ and SPF10, to detect most HPV types in aggregate. 
Subsequent restriction fragment length polimorfism (RFLP) or reverse line blot 
(RLB) steps can provide genotyping information. Commercial devices based on 
degenerated/consensus PCR and RLB are the AMPLIQUALITY HPV-TYPE 
EXPRESS (AB ANALITICA), the LINEAR ARRAY HPV Genotyping test 
(ROCHE) and the INNO-LiPA HPV Genotyping Extra (Innogenetics). These 
assays can be employed for second level analyses. Very similar to the above 
mentioned products, is one of the devices subject of this dissertation: the 
REALQUALITY RI-HPV STAR device (AB ANALITICA; for details see 
paragraph 2.3.1). High risk HPV specific devices based on Real-time PCR are 
available as well. They usually exploit all four channels of the Real-time 
equipment and provide specific genotyping information for HPV types 16 and 18, 
while concurrently detecting other high risk HPV types in a pooled result. 
Examples are the cobas HPV Test (ROCHE) and the Real Time High Risk HPV 
(Abbot) devices (11). These assays are quite versatile and can be used for both 
first level and second level assessments. The REALQUALITY RQ-HPV HR 
MULTIPLEX and the REALQUALITY RQ-HPV HR/LR MULTIPLEX devices, 
subjects of this dissertation, are based on the same technology.  
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RNA AND PROTEINS DETECTION METHODS 
So far no guidelines have been issued for the routine application of RNA or 
protein detection methods, thus, at the moment, they should be used only as 
additional tools for clinical decisions. The most widely used commercial method 
for RNA detection is NucliSENS HPV easyQ. It uses isothermal NASBA to 
detect the E6/E7 transcripts of five high risk HPV types (HPV 16, 18, 31, 33, 45). 
Protein based methods, usually, do not detect viral proteins, but rather p16INK4A, 
a host surrogate for HPV E7 (e.g. CINtec p16 Histology from VENTANA) (11). 
 
HPV NOVEL BIOMARKERS 
Ideal biomarkers should be able to pinpoint only the low and high grade lesions 
that will progress to cancer beyond any doubt.  
Methods for the detection of HPV genome integration are being developed. 
Epigenetics represents another hot area of research with groups detecting 
promoter CpG island hypermethylation either in L1 or E2 HPV genes (11). 
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2. PROJECT OVERVIEW 
 
2.1. SHORT SUMMARY 
 
In the first part of my PhD I worked on the new version of a product for HPV 
detection, recently developed at AB ANALITICA: the REALQUALITY RI-HPV 
STAR device. My task was to bring the original device to a higher level of 
analytical sensitivity for certain HPV genotypes as required by the World Health 
Organization (WHO).  The objective of increasing sensitivity was fulfilled. 
However, doubts on the robustness of the improved prototype emerged and the 
project was abandoned. As the possibility to reach the desired level of sensitivity 
by modifying an already existing device had vanished, I moved to the design of 
two new assays for HPV detection. The validation tests on the new devices proved 
they performed well and, thus, will be soon commercialized, under the names: 
REALQUALITY RQ-HPV HR MULTIPLEX and REALQUALITY RQ-HPV 
HR/LR MULTIPLEX. 
 
2.2. REQUIREMENTS FOR THE DEVICES TO BE DEVELOPED  
 
In 2009 the World Health Organization (WHO) released a manual for laboratories 
that perform HPV genotyping. In this manual, it is recommended that genotyping 
assays should detect, at a minimum, the fourteen most common high risk HPV 
types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) and the two LR 
HPV types targeted by a current HPV vaccine (6 and 11). Moreover, the WHO 
HPV LabNet has agreed that a laboratory that performs HPV DNA detection and 
typing - and, thus, also the assay used - should be considered proficient if it is able 
to detect 50 International Unit (IU) / 5 μl of DNA for HPV16 and HPV18, and 
500 genome equivalents (GE) / 5 μl of DNA for the other HPV types (34). 
For the sake of simplicity, in the following sections of this writing, the IU unit of 
measure will be substituted by GE. An International Unit is an arbitrary unit 
assigned to International Standards (ISs). ISs for HPV 16 and 18 DNA were 
established by the WHO ECBS (Expert Committee on Biological Standardization) 
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in 2008 and were assigned an IU content corresponding to their exact GE content 
(34). Compliance with the WHO requirements for HPV genotyping has been a 
pivotal aspect of my PhD work at AB ANALITICA.  
 
2.3. RATIONALE BEHIND THE DESIGN OF THE ASSAYS 
 
2.3.1. THE NEW VERSION OF THE REALQUALITY RI-HPV STAR 
DEVICE  
 
The original REALQUALITY RI-HPV STAR device allows to ascertain the 
presence of HPV genome in clinical cervical samples via Real-time PCR and 
melting curve analysis with intercalating dye technology. It uses consensus 
primers to amplify in aggregate most HPV types. For each samples it requires to 
perform two separate reactions, one for the pathogen target and the other for the 
internal control gene which is the HBB (hemoglobin, beta) gene. The device 
works on the StepOnePlus Real-Time PCR System (Applied Biosystems; “ABI 
StepOnePlus” in this writing). In Fig. 14, is a melting curve output obtained by 
amplifying with the HPV reaction mix three samples, i.e. an HPV negative 
sample, an HPV positive samples, and the HPV positive control (PC) provided 
with the device. Both the positive sample and the PC generate an HPV specific 
melting peak around 78°C. The negative sample also presents a peak, around 
68°C, which corresponds to primer dimers, a PCR byproduct. In order to allow the 
Fig. 14. Melting curve output for two 
samples, one negative and one positive, 
and the HPV positive control amplified 
with the HPV mix (ABI StepOnePlus, 
software v.2.2.2. 
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final user to distinguish between primer dimers and HPV specific peaks a cut-off 
temperature is provided.  
When developed in 2010, the REALQUALITY RI-HPV STAR product was 
meant as a screening device
4
, also allowing the possibility to directly genotype 
positive samples when associated to another product from AB ANALITICA: the 
AMPLIQUALITY HPV-TYPE device (for details see paragraph 4.1.11). The 
possibility to perform screening and genotyping all in once could have 
represented a strong marketing feature, as, the only screening device with FDA 
approval, at the time, the HC2 test (for details see paragraph 1.4.5) could not 
provide any genotyping information. However, penetrating the screening related 
segment of the market resulted more complicated than expected. Instead, the 
product was warmly welcomed by laboratories performing second level analysis, 
especially those dealing with a high number of samples, as the possibility to 
perform genotyping only on the subset of samples actually positive for HPV had 
the advantage to speed up the process considerably.  
The primers used in the PCR reaction of the original REALQUALITY RI-HPV 
STAR are the GP5+/GP6+ primers. As mentioned above, these are consensus 
primers, targeting the L1 region of HPV genome, which allow the detection of 
most HPV types in aggregate. The sensitivity they provide, though, is not equal 
for all types (62). A study conducted at AB ANALITICA, comparing the 
REALQUALITY RI-HPV STAR assay with the HC2 assay, reveled that the first 
has lower sensitivity for the following high risk HPV types: HPV 31, HPV52 and 
HPV 58. It also struggles with the detection of the possible high risk type HPV 
53. This is due to some mismatches the GP5+/GP6+ primers present when aligned 
to these genotypes (Fig. 15). Being the device mostly used as a second level test, 
it was considered appropriate to try to enhance its analytical sensitivity and the 
WHO requirements were taken as a reference. The new version of the device had 
to be based on the same technology and work on the same Real-time instrument. 
To achieve higher analytical sensitivity, the set up of the assay had to be modified 
                                                             
4 The device is not high risk HPV specific, as required for screening tests; however, direct genotyping of 
positive samples assures discrimination between high and low risk HPV type positive samples. Also, being 
based on a PCR reaction with GP5+/GP6+ primers, it should have been considered adequate as a first level 
test according to the landmark paper written by Meijer et al.(61). 
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considerably. The occasion was used to also improve an ergonomic aspect and 
amplify the target pathogen and the internal control gene in a single reaction, so as 
to halve the amount of work for the final user.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 15. Sequences of 23 HPV genotypes aligned against the GP5+/GP6+ primers. Mismatches are 
highlighted in yellow. 
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2.3.2. THE REALQUALITY RQ-HPV HR MULTIPLEX AND THE 
REALQUALITY RQ-HPV HR/LR MULTIPLEX DEVICES  
 
As the possibility to reach the required level of sensitivity by modifying an 
already existing device had vanished, the design of a completely new product for 
HPV detection became necessary.  In that occasion, it was decided to abandon the 
RLB technology, which can result cumbersome and time consuming for the final 
user, and rely only on Real-time PCR, which, on the contrary, is a very popular 
technology in the field of diagnostics, as it is simple and does not require too 
much hand-on time for the final user. This decision, obviously, influenced the 
design of the new assay radically, as, for example, it was no more possible to 
detect and genotype a very high number of different HPVs. Keeping that in mind, 
it was decided to primarily focus on those HPV types that should be detected by a 
genotyping assay in compliance with WHO requirements (HPV 16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, 59, 66 and 68). A possible strategy to detect and genotype 
all of them would have been that of designing a multiplex reaction with specific 
primers and rely on melting temperatures to discriminate among different types. 
This time, though, melting curve analysis was not considered as an option due to 
the problems experienced with the previous project. Instead, Real-time PCR with 
target specific primers and TaqMan fluorescent probes was employed.  
Another significant difference with respect to the previous project is that the target 
region of the new devices is E6/E7 instead of L1. This choice was due to both 
commercial and practical reasons. A key event in HPV-induced carcinogenesis is 
the integration of HPV genome in one of the host chromosomes, which can, in 
some rare cases, lead to the loss of L1, but not of E6/E7. Since residual integrated 
HPV DNA can, ultimately, be the only form of viral DNA present in infected 
cells, devices based on L1 detection might miss a small, but yet significant, 
portion of infections, whereas E6/E7 targeting devices will not (63). Targeting 
E6/E7, thus, represents a strong marketing feature, especially considering that 
devices from most competitors target L1 (11). On the practical side, being L1 
sequence the most conserved in HPV genome, the design of type specific primers 
and probes in that region would, probably, have been much more difficult. 
Finally, two separate assays, both based on a four fluorophore reaction, were 
42 
 
designed. The correspondence between targets and fluorophores for both the 
assays is summarized in table 5 and graphically represented in Fig. 16.  The first 
assay (assay 1 in this writing) was designed to detect all the high risk types from 
the WHO list, while also providing partial genotyping information, relative to 
HPV 16 and 18 positivity. Being both HPV 16 and 18 universally recognized as 
the most dangerous types, such a solution appeared to be the most convenient. 
The HBB gene was chosen as internal control gene. The second assay (assay 2 in 
this writing) was design to provide specific genotyping information for the two 
low risk types from the WHO list, HPV 6 and 11, while concurrently detecting 
other possible high risk HPV types (according to IARC classification (31)) in a 
pooled result. The possible high risk genotypes are not in the WHO list; However, 
they were added in order to offer a complete panel for HPV investigation. Again 
the HBB gene was chosen as the internal control gene.  
 
Assay JOE CY5 FAM ROX 
1 
HPV 16 
(higher risk) 
HPV 18 
(higher risk) 
HPV 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 66, 68  
(high risk) 
HBB 
(internal control) 
2 
HPV 6 
(low risk) 
HPV 11  
(low risk) 
HPV 26, 53, 67, 70, 73, 82 
(probabile high risk) 
HBB 
(internal control) 
 
Table 5. The correspondence between target genotypes and fluorophores for the newly designed assay is 
reported.  
 
Fig. 16. Graphic representation of the correspondence between targets and fluorophores for the first and the 
second assay. 
 
43 
 
Assay 1 was meant as an independent product and will be soon commercialized 
under the name REALQUALITY RQ-HPV HR MULTIPLEX. Assay 2, if 
associated to assay 1, provides the final user with a complete panel for HPV 
investigation. For this reason, assay 1 and assay 2, togheter, will be also proposed 
as an alternative product, under the name REALQUALITY RQ-HPV HR/LR 
MULTIPLEX. The assays were meant to work on both the 7500 Fast Dx Real-
Time PCR System (Applied Biosystems; “ABI 7500 Fast Dx” in this writing) and 
the Dx Real-Time System (BIO-RAD; “Biorad Dx” in this writing). 
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3. RESULTS 
 
3.1. SECTION OVERVIEW 
 
 This section is divided in two parts: in the first part, I describe the efforts made to 
enhance the performance of a product already available from AB ANALITICA’s 
catalogue, the REALQUALITY RI-HPV STAR device; in the second part, the 
work for the development of two new assays for HPV detection is presented. The 
first of the two assays (assay 1) was meant as an independent product and will be 
soon commercialized under the name REALQUALITY RQ-HPV HR 
MULTIPLEX. The second assay (assay 2) will be proposed, only in combination 
with the first assay, as an alternative product, under the name REALQUALITY 
RQ-HPV HR/LR MULTIPLEX.  
The rationale behind the design of all assays and their characteristics have been 
summarized in paragraph. 2.3. 
 
3.2. PART I: DEVELOPMENT OF THE NEW VERSION OF 
THE REALQUALITY RI-HPV STAR DEVICE 
 
3.2.1. SETTING THE REACTION UP 
 
3.2.1.1 Selecting primers for HPV detection 
 
Primers used in the PCR reaction of the original REALQUALITI RI-HPV STAR 
device are called GP5+ and GP6+. They are consensus primer targeting L1 region 
in HPV genome and allowing the detection of most HPV types in aggregate. The 
sensitivity they provide, though, is not equal for all the genotypes detected. A 
study conducted at AB ANALITICA, comparing the REALQUALITY RI-HPV 
STAR assay with a gold standard assay for HPV detection (HC2) reveled it has 
lower sensitivity for the following high risk HPV types: HPV 31, HPV 52 and 
HPV 58. It also struggles to detect the possible high risk type HPV 53. To 
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On the left, the RLB strips for samples 1, 2, 4 and 6 are shown. Both sets A and B  produced the anticipated 
result.    
 
enhance the assay sensitivity for these and other genotypes, new primers had to be 
added to the original pair. Only primers producing amplicons compatible with the 
AMPLIQUALITY HPV-TYPE genotyping system, however, could be selected. 
This meant that mainly degenerated versions of the original primer pair were 
considered. A study of the literature helped to identify two candidate primer sets 
(A and B) (64, 65). To ascertain which one worked better, end-point PCR was 
performed followed by both gel electrophoresis and reverse line blot with the 
AMPLIQUALITY HPV-TYPE device. Similarly good results on the critical 
genotypes were obtained on RLB strip (Fig. 17). On agarose gel, though, the 
superiority of set B emerged clearly as only HPV specific bands (~ 150 bp) were 
visible. Instead, primer set A produced multiple bands from both HPV positives 
and negative samples (Fig. 17). Initially, set A PCR was performed using the 
thermal profile reported in the reference paper. This paper suggested to use an 
annealing temperature (TA) of 42°C for the first 5 cycles and then of 64°C for 
other 45 cycles. Higher TAs for the first cycles were tested, however, aspecific 
bands could not be eliminated (Fig. 18). The presence of aspecific products would 
have definitely represented a problem for melting curve analysis, thus, only 
primer set B could be used for the following tests in Real-time PCR. 
Fig. 17. On the right, an agarose gel image of 6 
samples amplified with primer set A and B is 
shown. Samples 1, 3 and 5 are HPV negative 
samples. Sample 2 is positive for HPV 58; sample 
4 is positive for HPV 42, 43 and 52; sample 6 is 
an artificial sample containing HPV 54 plasmid 
DNA in genomic background. Set A produced 
multiple bands for both HPV negative and 
positive samples.  Mix   B   produced   only   a   
specific band (~ 150 bp) for the positive samples.   
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3.2.1.2. Selecting the internal control gene 
 
When analyzing a sample for a target that is not necessary present, it is advisable 
to simultaneously amplify an internal control (IC), i.e. a sequence we are sure to 
be present in our sample. Usually housekeeping genes or corresponding mRNAs 
are selected for the scope. The IC allows verifying whether the sample is suitable 
for amplification, has been extracted properly and does not contain inhibitory 
substances. With the previous setting, the IC and the pathogen target were 
amplified in two separate reactions. In the new version of the device the IC and 
the target pathogen had to be amplified in multiplex so as to halve the amount of 
work for the final user. However, this choice required the melting temperature of 
the IC to be sufficiently far from the range of melting temperatures covered by 
different HPVs
5
 in order to avoid confusion during result interpretation. 
In the original assay, the IC gene was the HBB (hemoglobin, beta) gene. Other 
devices in AB ANALITICA’s catalogue, though, use the TST (thiosulfate 
sulfurtransferase) gene as IC. These two genes were both considered as candidate 
ICs and tested to verify which one could have served the purpose better. In Fig. 19 
the melting curves obtained from a sample amplified with two multiplex mixes 
                                                             
5 Melting temperature of different HPV types amplified with degenerated primers are slightly 
different from one another as slightly different is the nucleotide composition of the corresponding 
amplicons, thus, they cover a range of temperatures. 
Fig. 18. An agarose gel image of two HPV negative sample, Neg 1 (wells 3, 4, 5, 6) and Neg 2 (wells 7, 
8, 9, 10), amplified with primer set A in gradient PCR (TA = 42-43-44-45 °C) is shown. No-temple-
controls (C-) were loaded in well 1 (TA = 42°C) and 2 (TA = 45°C). Positive controls (C+;  Plasmid DNA 
carrying the L1 region of HPV 54 diluted in genomic background) were loaded in well 11 (TA = 42°C) 
and 12 (TA = 45°C). At all TAs aspecific bands are visible in both the HPV negative samples and the 
positive controls.  
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are shown. One mix contained primers for HPV and HBB (blue curve), whereas 
the other contained primers for HPV and TST (red curve). For both the conditions 
three peaks are visible on the graph: the first two peaks correspond to primer 
dimers and HPV respectively and overlaps almost perfectly. The third peak 
corresponds to the internal control gene. HBB peaks is detected around 82°C (blue 
curve), whereas TST peak appears around 86°C (red curve). Being the efficiency 
of HPV amplification equal
6
 for both conditions, the only criterion took into 
account for choosing the IC gene was that of the distance from the HPV peak. 
Under this criterion, the TST gene represented a better choice. Moreover, another 
advantage was that the RLB strip of the  AMPLIQUALITY HPV-TYPE device 
already had a TST specific band, whereas no HBB specific bands were present. 
 
 
 
                                                             
6
 Inferred from HPV peak heights. 
Fig. 19. Melting plot obtained from a sample amplified with two multiplex mixes. One mix contained 
primers for HPV and HBB (blue curve), whereas the other contained primers for HPV and TST (red 
curve). The first two peaks correspond to primer dimers and HPV respectively; the third peak corresponds 
to the IC (ABI StepOnePlus, Software v. 2.2.2). 
48 
 
3.2.1.3. Selecting the intercalating dye 
 
The old mastermix was not adequate to sustain a PCR reaction with multiple 
primers and was substituted with one specific for multiplex reactions. The new 
mastermix, however, did not contain an intercalating dye which had to be added 
in order to allow melting curve analysis. Two different intercalating dyes (dye 1 
and 2), were tested in order to understand which one worked better. When tested 
the same samples, dye 1 gave stronger signals than dye 2 (Fig. 20) and was 
selected. 
 
 
 
 
 
3.2.1.4. Setting the conditions for the multiplex reaction 
 
The mastermix and the intercalating dye were used according to manufacturer 
instructions. The only thing that had to be set was primer concentration. Without 
going into the details, it is worth saying that, being the pathogen target (HPV) and 
the internal control (TST) amplified in multiplex, it was necessary to make sure 
that the two targets were not competing in a way that would have favored IC 
Fig. 20. Melting Curves obtained amplifying the same artificial sample with two different intercalating dyes. The 
sample contained a plasmid carrying the L1 sequence of HPV 16 (5 genome equivalent (GE) / µl) diluted in human 
genomic backgroud to mime a clinical sample. The signal from dye 1 is stronger than that from dye 2 (ABI 7500 Fast 
Dx, Software v. 1.4). 
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Fig. 21. A. The melting curve for a clinical sample positive for HPV 33 is shown (melting temperature = 
71.52°C). B. The melting curve for a clinical sample positive for HPV 81 is shown (melting temperature = 
77.58°C) (ABI StepOnePlus, software v. 2.2.2). 
amplification against pathogen target. This was assured by using primers for the 
IC at a concentration lower than that used for the pathogen target. 
 
3.2.1.5. Defining a range for HPV positive call after Real-time PCR 
 
The new assay was meant to work on the ABI StepOnePlus instrument just as the 
original REALQUALITY RI-HPV STAR device. On that instrument, a typical 
melting curve output for a sample positive for a single HPV type was a plot 
showing three melting peaks, the first peak corresponding to primer dimers, the 
second to HPV and the third to TST. 
Generally the primer dimer peak was around 65°C, the TST peak around 86°C and 
the HPV specific peaks somewhere in the middle. To make sure that the final 
users would have been able to distinguish HPV positive from negative samples, it 
was necessary to define a precise range for HPV positivity. In order to understand 
which genotypes generated melting peaks at the lowest and highest temperatures, 
50 clinical samples positive for different HPV types, in single and multiple 
infections, were tested. The analyzed genotypes were the following: HPV 6, 11, 
16, 18, 31, 33, 35, 39, 42, 43, 45, 51, 52, 56, 58, 59, 66, 68, 73, 81, 82. The lowest 
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melting temperatures were generated by HPV 33 positive samples (range 71.52 – 
71.67 °C; Fig. 21 A), whereas the highest corresponded to HPV 81 positive 
samples (range 77.06 – 77.58 °C; Fig. 21 B). The range for the positive call was, 
therefore, provisionally set between 71°C and 80°C, i.e. ~ 0.5 °C below the lowest 
recorded melting temperature and ~ 2.5°C above the highest. 
 
3.2.2. PRELIMINARY DATA ON PERFORMANCE 
 
3.2.2.1. Dye 1 stability after freezing and thawing 
 
Generally, for all the reagents that need to be stored at – 20°C, AB ANALITICA 
guarantees that they remain stable for up to three freeze and thaw cycles. The 
mastermix chosen for the new assay had already been used in other kits and had 
resulted stable, whereas the chosen intercalating dye had never been tested before. 
For this reason, before proceeding, it was necessary to make sure that the dye, 
diluted in the mastermix, would have tolerated repeated cycles of freezing and 
thawing with no significant changes in its performance. To check that, I produced 
a stock solution of dye 1 added mastermix. I also produce two artificial samples 
by diluting plasmids carrying the L1 sequence of HPV 16 and 18 in genomic 
DNA (conc. 50 genome equivalents (GE) / µl) to mime clinical samples. The mix 
containing the dye was tested on the artificial samples on the day of its production 
to set a reference and then stored at -20 °C. After a week it was thawed and tested 
again. The procedure was repeated for the two following weeks. The artificial 
samples were aliquoted on the day of their production and stored at -20°C until 
use, so that a fresh aliquot would have been available for each of the tests. In this 
way, any change in the test results would have been due to degradation of dye 1 
and not due to degradation of plasmids. No relevant changes in performance were 
observed as the height of the melting peaks for HPV and TST remained constant 
from the first to the last test (Fig. 22). Dye 1 was, therefore, considered adequate 
for setting up the reaction for the new assay. 
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Fig. 22. The result of a test on the stability of dye 1 after 3 freeze and thaw cycles is presented. Red curves 
were obtained from the amplification of a sample containing HPV 16 plasmids in genomic background (conc. 
50 GE/µl), green curves were obtained from the amplification of a sample containing HPV 18 plasmids in 
genomic background (conc. 50 GE/µl). The result of the run performed at time 0 (day of production of the 
reaction mix containig dye 1) is reported in A. The result of the run performed at time 1 (one week after the 
reaction mix was produced; one freeze and thaw cycle) is reported in B; The result of the run performed at 
time 2 (two weeks after the reaction mix was produced; two freeze and thaw cycles) is reported in C; The 
result of the run performed at time 3 (three weeks after the reaction mix was produced; three freeze and thaw 
cycles) is reported in D. No changes in the performance of the dye 1 containing mix were observed (ABI 
7500 Fast Dx, software v. 1.4).  
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3.2.2.2. Preliminary tests on the analytical sensitivity of the newly designed 
Real-time PCR reaction in combination with the AMPLIQUALITY HPV-
TYPE assay 
 
The WHO recommends that genotyping assays should detect, at a minimum, the 
fourteen most common high risk HPV types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 66 and 68) and the two low risk HPV types targeted by a current 
HPV vaccine (HPV 6 and 11). Moreover, the WHO HPV LabNet has agreed that 
a laboratory that performs HPV DNA detection and typing – and, thus, also the 
assay used - should be considered proficient if it is able to detect 50 genome 
equivalents (GE) / 5 μl of HPV16 and HPV18 DNA, and 500 GE / 5 μl of the 
other HPV types. The newly designed assay, as most commercial assays, requires 
exactly 5 μL of DNA for each single reaction, thus, the limit concentrations can 
also be expressed as GE/reaction or GE/rx. 
To check whether the newly designed assay was in compliance with the WHO 
requirements I tested, on the ABI StepOnePlus instrument, all the HPV plasmids 
available, at the time, at AB ANALITICA and then genotyped them with the 
AMPLIQUALITY HPV-TYPE device (for details on this product see paragraph 
4.1.11). The genotypes from the WHO list I tested were the following: HPV 16, 
18, 31, 33, 39, 51, 52, 59, 66, 68 and 6. I also checked the assay sensitivity for 
other possible high risk genotypes, i.e. HPV 53 and 73, as I had the respective 
plasmid at disposal. The plasmids were diluted in genomic background to mime 
clinical samples. The assay succeeded in detecting all tested genotypes at the 
required limit concentration (Fig. 23). 
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3.2.2.3. Preliminary tests on the clinical specificity of the Real-time PCR 
reaction 
 
To assess the clinical specificity of the newly designed assay, 150 HPV negative 
clinical samples previously tested with a reference method (AMPLIQUALITY 
HPV-TYPE EXPRESS v 2.0, AB ANALITICA) were analyzed on the ABI 
StepOnePlus instrument. Accordingly to the provisionally defined range for HPV 
positivity (71 – 80 °C), seven samples resulted positive after Real-time PCR. 
These samples were subjected to RLB with the AMPLIQUALITY HPV-TYPE 
device to check whether they were actually positive for HPV. In all cases the RLB 
gave a negative result, meaning that neither a HPV type specific band nor the 
HPV universal band were visible on the strips. To further confirm this result the 
PCR products for the critical samples were run on agarose gel and again no HPV 
specific bands were observed, thus the samples were regarded as false positives, 
reasonably caused by the amplification of aspecific PCR products. In table 6 the 
O 
Fig. 23. Melting temperature peaks and 
reverse line blot (RLB) results for 13 
artificial samples positive for  different HPV 
genotypes. For each genotype three bands 
are visible on the RLB strip: the TST band 
(below the black line at the top of the strip 
box), the universal HPV band (below the 
TST band; it might appear pale in case most 
HPV PCR product hybridized to the specific 
HPV type band) and the specific HPV type  
band. A. HPV 16 plasmid in genomic 
background (conc. 50 genome equivalents 
(GE) / rx).  B. HPV  18  plasmid  in genomic 
background (conc. 50 GE/rx). C. HPV 31   plasmid   in genomic background (conc. 500 GE/rx). D. HPV 
33 plasmid in genomic background (conc. 500 GE/rx).  E.  HPV 39  plasmid in genomic background 
(conc 500 GE/rx). F.  HPV 51  plasmid in genomic background (conc. 500 GE/rx). G. HPV 52 plasmid in 
genomic background (conc. 500 GE/rx). H. HPV 59 plasmid in genomic background (conc. 500 GE/rx). I. 
HPV 66 plasmid in genomic background (conc. 500 GE/rx). L. HPV 68 plasmid in genomic background 
(conc. 500 GE/rx). M. HPV 6 plasmid in genomic background (conc. 500 GE/rx). N. HPV 53 plasmid in 
genomic background (conc. 500 GE/rx). O. HPV 73 plasmid in genomic background (conc. 500 GE/rx) 
(ABI StepOnePlus, software v. 2.2.2). 
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melting temperatures recorded by the Real-time PCR instrument for those seven 
false positive samples are reported. 
 
SAMPLE 
MELTING 
TEMPERATURE 
1 74.78 
2 71.08 
3 71.25 
4 71.40 
5 72.28 
6 78.56 
7 78.70 
 
Considering these seven false positive sample the clinical specificity of the Real-
time PCR assay would have been 95.3%. However, it has to be noted that the 
higher limit of the HPV positivity range could have been lowered to 78°C, 
maintaining it 0.4 °C above the highest HPV specific melting temperature ever 
recorded on previous tests (see paragraph 3.1.1.5). According to this new range 
(71 – 78 °C) the specificity would jump to 96.7 % as samples 6 and 7 would no 
more be considered HPV positive.  
 
3.2.2.4. Doubts on the robustness of the newly designed Real-time PCR assay 
and end of the project 
 
The specificity value obtained testing 150 HPV negative samples could have been 
considered acceptable. However, the analysis of the melting curves for those 
samples highlighted a phenomenon that had to be taken into serious consideration: 
in 22 samples (15 % of all analyzed samples) the melting peaks corresponding to 
primer dimers presented a shoulder invading the lower limit of HPV positivity 
range. The Real-time PCR instrument never recognized those shoulders as actual 
peaks, nevertheless, they were clearly visible by eye (Fig. 24). First of all, such an 
output could have generated confusion in the final user. Secondly, it was not 
possible to foresee whether the problem could have exacerbated under standard 
production conditions, which require frequent changes in the reagent batches 
used, and whether, at a certain point, the Real-time PCR instrument would have 
started to recognize those shoulders as real peaks. I tested different reaction 
Table 6. The melting temperature 
recorded for seven HPV negative 
samples which resulted positive after 
Real-time PCR are reported. 
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conditions in order to solve the problem, mainly acting on primer concentration 
and on the thermal profile, however no relevant improvements were 
accomplished. On that premise, abandoning the project was considered the only 
feasible possibility, as the risk of putting on the market a product generating an 
uncontrollable number of false positive results was not acceptable. 
 
 
 
 
 
 
 
 
Fig. 24. Melting curves, obtained from the amplification of two negative samples, presenting primer dimer 
shoulders invading the range of HPV positivity (ABI StepOnePlus, software v. 2.2.2). 
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3.3. PART II: DEVELOPMENT AND VALIDATION OF THE 
REALQUALITY RQ-HPV HR MULTIPLEX AND THE 
REALQUALITY RQ-HPV HR/LR MULTIPLEX DEVICES 
 
3.3.1. SETTING UP THE REACTIONS FOR ASSAY 1 AND ASSAY 2
7
  
 
3.3.1.1. Designing specific primers and probes  
 
Primes from the previous project had been selected from literature; they were 
consensus degenerated primers targeting L1, the most conserved region in HPV 
genome and historically preferred, especially when desiring to amplify most HPV 
types in aggregate. This time, primers had to be target specific, thus they were 
designed in a different region, called E6/E7. This region, beside being less 
conserved among HPVs, presents another significant advantage: it is never lost 
during HPV infections evolving to cancer.  
Many aspects had to be considered before selecting primers and probes. A 
phylogenetic tree was used as a guide to predict which types could have been, 
more likely, the cause of aspecific PCR products.  
Also, before starting the acutal design, several papers providing primer and probe 
sequences targeting the HPV E6/E7 region were consulted. Genotype specific 
primers form the literature tended to be concentrated in delimited portions of the 
E6/E7 sequence suggesting they might have been favorable for some reason. 
When possible, primers and probe were designed in those regions.  
Once selected a candidate primer or a probe, analytical specificity was evaluated 
in silico by BLAST analysis. Primers and probes that resulted specific for their 
target could be ordered. 
 
 
 
                                                             
7 Assay 1 corresponds to the REALQUALITY RQ-HPV HR MULTIPLEX device, whereas assay 
1 and 2, together, correspond to the REALQUALITY RQ-HPV HR/LR MULTIPLEX device (for 
details on assay design see paragraph 2.3.2). 
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3.3.1.2 Testing primers and probes on samples 
 
Primers and probes were tested in simplex against three kind of samples: 
1) cervical samples positive for the target HPV type; 
2) cervical samples positive for possibly cross-reactive genotypes
8
; 
3) HPV negative cervical samples (to check cross-reactivity with human genome). 
In Fig. 25 an amplification plot is shown; it was obtained while testing HPV 52 
primers and probe on three samples, previously tested with the reference method 
AMPLIQUALITY HPV-TYPE EXPRESS v 3.0 (AB ANALITICA). Two were 
samples positive for HPV 52 and produced sigmoid amplification curves; one was 
a sample positive for HPV 33, which gave no amplification curve. The reaction, 
therefore, was correctly amplifying the target genotype while giving no aspecific 
signals in presence of the possibly cross-reactive HPV 33 genotype.  
For some genotypes, different primer pairs were ordered and compared to select 
the one performing better, before ordering the respective probe. Comparison was 
done via Real-time PCR with intercalating dye followed by gel electrophoresis. In 
Fig. 26, is a gel picture showing the PCR products obtained testing two different 
primer pairs for HPV 58 in parallel on the same samples. The top line and the 
bottom line were loaded with the PCR products obtained with primer pair 1 and 2 
respectively. Columns 1-2 correspond to sample positive for HPV 58, columns 3-
5 to samples positives for HPV 33, columns 6-7 to samples negative for HPV and 
column 8 to the no-template-control (C-). Both primer pairs produced a specific 
band (~100 bp) in presence of HPV 58 genome (top line and bottom line, columns 
1-2). Only primer pair 2, though, resulted specific as it gave no amplification 
products in presence of HPV 33 or human genomic DNA (bottom line, columns 
3-7). Primer pair 1, instead, was amplifying also human genomic DNA as a band, 
slightly higher than that specific for HPV 58, is visible in the samples positive for 
HPV 33 (which also contain genomic DNA) as well as in those negative for HPV 
(top line, columns 3-7). Primer pair 2 for HPV 58 was selected to set up the 
reaction for assay 1.  
                                                             
8 Non-target genotypes presenting only e few mismatches with the primers of interest when 
analyzed with BLAST (for details on BLAST analysis see paragraph 4.2.10.) 
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Once tested in simplex, primers and probes had to be tested in multiplex as well. 
Assay 1 and assay 2 mixes, however, were not assembled all in once, but rather by 
adding primer pairs and the respective probes two by two. Each time, the partial 
mixes were tested on known HPV positive and negative clinical samples in order 
to check whether the newly added oligos could interfere with the others.  
 
 
 
Fig. 25. An amplification plot is shown. It was obtained while testing HPV 52 primers and probe on three 
samples, previously tested with the reference method AMPLIQUALITY HPV-TYPE EXPRESS v 3.0 (AB 
ANALITICA). Two were samples positive for HPV 52 and produced sigmoid amplification curves, one was 
a sample positive for HPV 33 which gave no amplification curve (ABI 7500 Fast Dx, software v. 1.4). 
 
 
Fig. 26. Gel picture showing the PCR products obtained 
testing two different primer pairs for HPV 58 in parallel 
on the same samples. The top line and the bottom line 
were loaded with the PCR products obtained with primer 
pair 1 and 2 respectively. Columns 1-2 correspond to 
sample positive for HPV 58, columns 3-5 to samples 
positives for HPV 33, columns 6-7 to samples negative for 
HPV and column 8 to the negative control (C-). Only 
primes pair 2 is specific for HPV 58. 
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3.3.1.3. Setting the conditions for the multiplex reactions 
 
The mastermix chosen for the assays already contained all the elements needed 
for amplification. The only thing that had to be set was primer and probe 
concentration. Without going into the details, they were set in order to favor target 
pathogen (HPV) amplification against internal control (HBB) amplification.  
Florescence saturation phenomena had also to be taken into account. In Fig. 27, 
the amplification curves obtained by amplifying 30 samples with assay 1 on the 
Biorad Dx instrument are shown in “no baseline subtraction mode”. The signals 
measured in FAM channel are represented in blue, whereas those measured in 
JOE, Cy5 and ROX are in green, purple and orange respectively. It is clearly 
visible that the FAM baseline fluorescence is much higher than that of the other 
fluorophore and close to the recording limit of the machine. This is due to the fact 
that, in assay 1, FAM labeled probes are 12, whereas JOE, Cy5 and ROX probes 
are one for each of the fluorophore. The situation is similar in assay 2, even 
though FAM probes are only six.  
 
 
Fig. 27. The amplification curves obtained by amplifying 30 samples with assay 1 are shown in 
“no baseline subtraction mode”. The signals measured in FAM channel are represented in blue, 
whereas those measured in JOE, Cy5 and ROX are in green, purple and orange respectively. FAM 
baseline is much higher than that of the other fluorophores (Biorad Dx, software v. 1.7). 
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Being the FAM baseline so high, amplification of FAM targets could easily bring 
the system to saturation. In such a case the amplification curve appears sharp-
cornered, the corner corresponding to the point where the instrument is no more 
able to record fluorescence increase due to saturation. To limit this problem and 
keep the FAM fluorescence baseline as low as possible, the concentration of the 
corresponding probes had to be much lower than that of the HPV probes labeled 
with the other fluorophores (Fig. 28). 
 
 
Fig. 28. The amplification curves for a sample positive for HPV 52 (FAM signal) is presented. The 
sharp-cornered curve was obtain using FAM probes at the same concentration of the other HPV 
probes. The sigmoid curve was obtained with FAM probes at a lower concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
63 
 
3.3.2. PERFORMANCE OF ASSAY 1 
 
3.3.2.1. Validation on clinical samples: clinical sensitivity and specificity, and 
genotype concordance 
 
The assay was meant to work on ABI 7500 Fast Dx and Biorad Dx, thus it was  
validated on both Real-time instruments. A total number of 320 clinical samples 
was used. The  sample composition was as represented in the pie chart below (Fig. 
29).  
 
 
 
The samples were tested both with assay 1 and a reference method 
(AMPLIQUALITY HPV-TYPE EXPRESS, v. 3.0; AB ANALITICA). In case of 
discordant results, sequencing was used to confirm the genotype composition of 
samples. In particular, if one method detected a genotype not detected by the 
other, the sample was amplified in simplex, using primers specific for the 
genotype of interest, and then the PCR product was sent for sequencing. The 
chosen reference method is a full-genotyping method based on end-point PCR and 
RLB, thus, in case it detected a genotype not detected by assay 1, it was 
immediately clear which one it was. The opposite situation was more complicated 
320 clinical samples 
244 cervical swab samples 
30 oral swab samples 
25 urethral swabs samples 
9 QCMD 2014 samples 
6 urethral biopsies 
4 anal biopsies 
1 foreskin biopsy 
1 vaginal biopsy 
Fig. 29. Pie chart representing the composition of the 320 clinical samples used to validate assay 1. 
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as assay 1 only provides partial genotyping information. This means that, when an 
unexpected JOE or Cy5 signal was observed, the presence of HPV 16 or 18 was 
obviously suspected; whereas, in case of FAM unexpected signals, the responsible 
genotype could have been any of the 12 genotypes detectable in that channel. A 
possible way to confirm the presence of one of the “FAM genotypes”, in such a 
circumstance, would have been to amplify the sample with 12 simplex reactions, 
one for each of the candidate genotypes, and then proceed with sequencing. To 
preserve samples, though, I decided to opt for a different approach, that only 
required to perform five simultaneous Real-time PCR reactions. Each of the five 
reactions was performed using all the primers from assay 1, but only a subset of 
probes. A scheme of how probes were allocated among the five reactions, called 
A, B, C, D and E, is represented in Fig. 30. In brief, mix A contained the probes 
for HPV 31, 33, 35 and 39; mix B the probes for HPV 45, 51, 52 and 56; mix C 
the probes for HPV 58, 59, 66 and 68; mix D the probes for HPV 31, 45, 58, 33, 
51 and 59; and mix E the probes for HPV 33, 51, 59, 35, 52 and 66. According to 
this scheme, if present in mono-infection, each genotype would have given an 
univocal pattern of positivity among the five mixes. For example, with an HPV 31 
positive sample, a FAM signal would have been observed only from mixes A and 
D; with HPV 33 the FAM signals would have been from A, D and E; with HPV 
35 from A and E; with HPV 39 only from A and so on for all the other genotype. 
Once understood which genotype was responsible for the signal, it was amplified 
in simplex and send for sequencing. In Fig. 31, is the amplification plot obtained 
by amplifying, with mixes A, B, C, D and E, a sample that resulted negative for 
Fig. 30. Scheme representing how FAM 
probes of assay 1were allocated among 
mixes A, B, C, D and E. 
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the reference method, but produced a signal in the FAM channel when tested with 
assay 1. Mixes C and D gave a positive signal indicating the presence of HPV 58, 
later confirmed by sequencing. 
 
Once analyzed all the 320 samples, clinical sensitivity  and clinical specificity of 
assay 1 could be calculate. Clinical sensitivity corresponds to the number of 
samples correctly identified by assay 1 as positive divided by the number of all 
the positive samples; whereas specificity corresponds to the number of samples 
correctly identified as negative by assay 1 divided by the number of all the 
negative samples. In this context, positives samples were considered to be those 
samples that resulted positive, for one of the 14 genotypes comprised in assay 1 
panel, either with both assay 1 and the reference method or with one of the two 
methods and sequencing. All the other sample, comprising both HPV negative 
samples and samples positive for HPV genotypes different from the 14 comprised 
in assay 1 panel, were considered as negative. According to the above definitions, 
positive samples were 141 and negative samples were 179. Clinical sensitivity and 
specificity on the ABI 7500 Fast Dx instrument were 99.3% and 98.9% 
respectively; Clinical sensitivity and specificity on Biorad Dx were 97.8% and 
Fig. 31. On the left side of the picture, is a sample plate showing 5 samples that were all 
amplified with mixes A, B, C, D and E. On the right side, is the amplification plot obtained for 
sample 3 (gray wells on the sample plate). Only mixes C and D produced an amplification 
curve indicating the presence of HPV 58. 
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99.4% respectively. According to the validation plan
9
, any result above 95% 
would have been considered adequate.  
With data obtained from the 320 samples, also genotype concordance between 
assay 1 and the reference method could be calculated. This parameter corresponds 
to the number of HPV genotypes identified by both methods divided by the total 
number of identified genotypes (genotypes identified by both assays + extra 
genotypes identified with assay 1 + genotypes not identified with assay 1). 
Genotype concordance on ABI 7500 Fast Dx was 92 %, whereas on Biorad Dx 
was  90.6 %.  
 
3.3.2.2 Analytical sensitivity  
 
As detailed in previous paragraphs, the WHO considers proficient an HPV 
genotyping assay able to detect at least 50 genome equivalents (GE) / 5 μl of 
HPV16 and HPV18 DNA, and 500 GE / 5 μl of the DNA of HPV 31, 33, 35, 45, 
51, 52, 56, 58, 59, 66 and 68. Also, as assay 1, requires 5 μl of DNA extract per 
reaction, the above concentrations can be expressed as GE/rx.  
The analytical sensitivity of assay 1 was assessed with several approaches. For 
HPV 16 and 18, it was calculated with probit analysis. To produce a sufficient 
number of data for the model, artificial samples containing the genotype of 
interest at five different concentratios (7.5 – 5 – 2.5 – 1.25 – 0.5 GE/rx) were 
tested in 8 replicates for 3 consecutive runs. The estimated limits of detection 
(LODs) for HPV 16 and 18 were 3.4 GE/rx (p = 0.05) and 4 GE/rx (p = 0.05) 
respectively (Fig. 32). The exact LODs for the other HPV targets were not 
calculated. However, assay 1 was tested with the “Global HPV LabNet 2013 HPV 
DNA Genotyping Proficiency Panel” (WHO proficiency panel in this writing). 
This panel comprises 46 artificial samples containing purified whole genomic 
plasmids of HPV 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68a and 
68b in a background of human cellular DNA. The samples are prepared to include 
single types and mixtures at limit concentrations and 10-fold lower 
concentrations. The composition of the panel is summarized in table 7. All 
samples in the panel were correctly identified. Therefore, the limit of detection of 
                                                             
9
  A document compiled before starting the validation process (for details see section 5). 
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Fig. 32. Probit analysis output showing the limit of detection of assay 1 for HPV 16 (graph on 
the left; 3.4 GE/rx (p = 0.05)) and HPV 18 (graph on the right; 4 GE/rx (p = 0.05)) (R 
software). 
assay 1 for the 14 detectable genotypes is below the limit concentrations required 
by WHO. It is worth noting that sample 30 contains 5 GE/5μl (i.e. 5 GE/rx) of 
HPV 16 plasmid DNA and was correctly genotyped, thus, confirming the result 
obtained with probit analysis. 
 
WHO SAMPLE GENOTYPE 
CONCENTRATION 
(GE/5μl) 
1 58 50 
2 18 50 
3 39, 45, 52, 56, 68b 500 
4 33 50 
5 52 500 
6 68b 500 
7 6 500 
8 39 50 
9 66 500 
10 35, 59, 66, 68a 500 
11 16 50 
12 31 50 
13 52 50 
14 68a 500 
15 negative 0 
16 51 500 
17 31 500 
18 11, 31, 33, 58 500 
19 56 50 
20 68b 50 
21 35, 59, 66, 68a 50 
22 6 50 
23 45 50 
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WHO SAMPLE GENOTYPE 
CONCENTRATION 
(GE/5μl) 
24 59 50 
25 39, 45, 52, 56, 68b 50 
26 18 5 
27 35 50 
28 59 500 
29 6, 16, 18, 51 500 
30 16 5 
31 35 500 
32 58 500 
33 11, 31, 33, 58 50 
34 11 50 
35 45 500 
36 66 50 
37 6, 16, 18, 51 50 
38 11 500 
39 33 500 
40 39 500 
41 56 500 
42 68a 50 
43 51 50 
A none 0 
B 16 2500 
C 16 25 
 
Table 7. Composition of the WHO proficiency panel from 2013. 
 
The WHO proficiency panel was from 2013; when I used it, it was too late submit 
the output data an receive an official response from WHO. Assay 1, though, could 
participate to a different external quality assessment (EQA) program i.e. the 
QCMD (Quality Control for Molecular Diagnostics) 2014 Human Papillomavirus 
DNA EQA Programme. The QCMD panel comprised 10 samples, composed as 
summarized in table 8. Assay 1 was able to correctly genotype all 6 core samples  
and 9 out of 10 samples, when considering also the educational samples (Fig. 33). 
Moreover, it has to be outlined that the only sample that was not correctly 
identified is described as “low viral load HPV 16 (SiHa)” and, as the QCMD 
referred, did not result positive also when analyzed by two external testing 
laboratories using the Cobas HPV assay (ROCHE) and the HC2 assay (QIAGEN) 
respectively. The QCMD also referred that only the 87.2% of participant reported 
100% of core samples correctly. Data relative to this EQA program, thus, 
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represent a further confirmation that the analytical sensitivity of assay 1 is 
adequate for the scope of genotyping. 
 
SAMPLE MATRIX CONTENT STATUS TYPE 
HPV14-02 
Pre servCyt + 
BSM 
HPV16 (Caski) Positive Core 
HPV14-06 
Pre servCyt + 
BSM 
HPV18 (Hela) Positive Core 
HPV14-01 
Pre servCyt + 
BSM 
HPV45 (CC10b) Positive Core 
HPV14-09 
Pre servCyt + 
BSM 
HPV16 /18 (Caski/Hela) Positive Core 
HPV14-10 
Pre servCyt + 
BSM 
Lo w Vi r al Lo ad HPV16 
(SiHa) 
Positive Educational 
HPV14-08 
Pre servCyt + 
BSM 
HPV5 1&5 2 (clinical sample) Positive Educational 
HPV14-04 
Pre servCyt + 
BSM 
HPV5 2 &5 6 (clinical sample) Positive Educational 
HPV14-07 
Pre servCyt + 
BSM 
HPV5 4&5 6 (clinical sample) Positive Educational 
HPV14-03 
Pre servCyt + 
BSM 
HPV Negative (BSM) Negative Core 
HPV14-05 
Pre servCyt + 
BSM 
HPV Negative (BSM) Negative Core 
 
Table 8. Composition of the QCMD panel from 2014. 
 
 Fig. 33. Snapshot from the QCMD individual report relative to assay 1 performance in the context of the 
QCMD 2014 Human Papillomavirus DNA EQA Programme. 
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3.3.2.3 Analytical specificity 
 
In order to assess the analytical specificity of assay 1, it was necessary to test it 
with samples positive for possibly cross-reactive targets such as HPV types 
different from those detected by the assay and other pathogens, especially those 
infecting the ano-genital district. 
As for the first subset of samples, the validation data could be used. Among the 
samples regarded as negative, there were also 54 samples positive for possible 
high risk and low risk HPV types (HPV 6, 11, 26, 40, 42, 43, 44, 53, 54, 61, 62, 
67, 70, 73, 81, 82, 84, 87, 89and 90). Of these, two samples (3.7 %) resulted 
positive (late FAM signal) once analyzed on the ABI 7500 Fast Dx instrument. 
The genotypes detected with the reference method were HPV 6 and 87 in one case 
and HPV 40 and 84 in the other. The presence of an extra high risk genotype 
could not be confirmed by sequencing as no positive signals were obtained with 
mixes A, B, C, D and E (see paragraph 3.3.2.1). Cross-reactivity with those 
genotypes, however, was excluded as other samples positive for the same 
genotypes did not produced unexpected FAM signals. 
As for the second subset of samples, those positives for other pathogens, 18 
samples were analyzed (table 9). Only sample 14, positive for Trichomonas 
vaginalis, gave an unexpected positive signal. Being a clinical sample, it could 
also have been positive for an high risk HPV. Therefore, it was analyzed with 
another method (AMPLIQUALITY HPV-TYPE EXPRESS, v. 3.0; AB 
ANALITICA) and the presence of an high risk HPV type (HPV 66) was 
confirmed (Fig. 34). As other samples positive for Trichomonas vaginalis did not 
produce aspecific signals, cross-reactivity with that pathogen, as with the others 
tested, was exclude. The assay performance relative to analytical sensitivity was 
regarded as adequate. 
 
SAMPLE TYPE PATHOGEN 
1 Artificial sample Adenovirus 
2 Artificial sample Candida albicans 
3 Urine  Cytomegalovirus 
4 Urine Chlamydia trachomatis 
5 Artificial sample Chlamydia trachomatis / Neisseria gonorrhoeae 
6 Artificial sample Gardnerella vaginalis 
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SAMPLE TYPE PATHOGEN 
7 Artificial sample Herpes simplex 1 
8 Urethral swab Herpes simplex 1-2 
9 Urethral swab Herpes simplex 2 
10 Artificial sample Mycoplasma genitalium 
11 Artificial sample Mycoplasma hominis 
12 Artificial sample Neisseria gonorrhoeae 
13 Vaginal discharge Trichomonas vaginalis 
14 Vaginal swab Trichomonas vaginalis 
15 Vaginal discharge Trichomonas vaginalis 
16 Urethral swab Ureaplasma parvum 
17 Artificial sample Ureaplasma parvum 
18 Artificial sample Ureaplasma urealyticum 
 
Table. 9. Samples positive for pathogen different from HPV. 
 
 
 
 
Fig. 34. Reverse line blot output for sample 14 (AMPLIQUALITY HPV-TYPE EXPRESS, v. 3.0). 
 
3.3.2.4. Intra and inter-assay variability 
 
Clinical samples carrying HPV mono-infections were used to calculate the intra 
and inter-assay variability for the 14 genotypes detected by assay 1. As for HPV 
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68, samples for both HPV 68a and HPV 68b variants were used, the total number 
of analyzed samples is 15 instead of 14.  
 
INTRA-ASSAY VARIABILITY 
To measure inter-assay variability, the 15 samples were amplified in eight 
replicates in a single run. For each genotype, the coefficient of variation (CV) was 
calculated as the ratio of standard deviation multiplied for 100 to the mean of the 
Cycle threshold (Ct) values of the eight replicates. The Ct values for the eight 
replicates of the sample positive for HPV 16 are reported in table 10. 
REPLICATE Ct 
1 29.5701 
2 29.579 
3 29.7908 
4 29.7193 
5 29.7651 
6 29.6254 
7 29.7672 
8 29.7279 
 
Table 10. Ct values for the eight replicates of the sample positive for HPV 16 used to calculate the intra-assay 
CV value. 
The standard deviation (σ) for values in table 10 is 0.09 and the mean (μ) is 29.69. 
Thus, the intra-assay CV ( 
       
 
 ) for HPV 16 is 0.3%. The intra-assay CV values 
for all the other genotypes are reported in table 12. 
 
INTER-ASSAY VARIABILTY 
To measure inter-assay variability, the 15 samples were amplified in three 
consecutive runs. For each genotype the CV was calculated as the ratio of 
standard deviation multiplied for 100 to the mean of the Cycle threshold (Ct) 
values of the three runs. The Ct values for the three runs of the sample positive for 
HPV 16 are reported in table 11. 
 
RUN Ct 
1 29.7858 
2 29.8157 
3 29.7882 
 
Table 11. Ct values corresponding to the sample positive for HPV 16, measured in three consecutive runs. 
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The standard deviation (σ) for values in table 11 is 0.02 and the mean (μ) is 29.80. 
Thus, the inter-assay CV ( 
       
 
 ) for HPV 16 is 0.06%. The inter-assay CV 
values for all the other genotypes are reported in table 12.  
 
TARGET Intra-assay CV (%) Inter-assay CV (%) 
HPV 16 0.30 0.06 
HPV 18 0.17 0.15 
HPV 31 0.63 1.48 
HPV 33 0.48 0.59 
HPV 35 1.03 0.43 
HPV 39 0.40 0.93 
HPV 45 1.28 0.92 
HPV 51 0.89 0.86 
HPV 52 0.76 0.90 
HPV 56 0.42 0.17 
HPV 58 0.71 0.39 
HPV 59 0.67 0.62 
HPV 66 0.84 0.77 
HPV 68a 0.71 0.16 
HPV 68b 0.63 0.45 
 
Table 12. Intra-assay CV and inter-assay CV values for 15 genotypes. 
 
The CV values for assay 1 are all below 1.5%, indicating that the assay has high 
repeatability.  
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3.3.3. PERFORMANCE OF ASSAY 2 
 
3.3.3.1. Validation on clinical samples: clinical sensitivity and specificity 
 
As assay 1, also assay 2 was meant to work on ABI 7500 Fast Dx and Biorad Dx, 
thus it was  validated on both Real-time instruments. A total number of 192 
clinical samples was used. 165 were cervical swab samples, whereas 27 were 
urethral swab samples.  
The same approach used for assay 1 validation was used also here. All samples 
were tested with a reference method (AMPLIQUALITY HPV-TYPE EXPRESS 
v. 3.0). HPV composition of discordant samples was verified by end point PCR 
followed by sequencing.  
In case of unexpected FAM signals from assay 2, the genotype generating the 
signal was identified using four simultaneous reactions (called F, G, H, I). Each of 
the four reactions contained all the primers from assay 2 but only a subset of 
probes. A scheme of how probes were allocated among the four reactions is 
represented in Fig. 35. 
 
 
 
 
 
 
According to this scheme, if present in mono-infection, each genotype would have 
given an univocal pattern of positivity among the four mixes. For example, with 
an HPV 26 positive sample, a FAM signal would have been observed only from 
mixes F and I. 
In this context, positives samples were considered to be those samples that 
resulted positive, for one of the 8 genotypes comprised in assay 2 panel, either 
with both assay 2 and the reference method or with one of the two methods and 
sequencing. All the other sample, comprising both HPV negative samples and 
samples positive for HPV genotypes different from the 8 comprised in assay 2 
panel, were considered as negative. According to the above definitions, of the 192 
Fig. 35. Scheme representing how 
FAM probes of assay 2 were allocated 
among mixes F, G, H, and I. 
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tested samples, 83 were positive and 109 were negative. All samples were tested 
on ABI 7500 Fast Dx. 81 out of 83 samples were correctly identified as positive, 
thus, clinical sensitivity was 97.6%; whereas 108 out of 109 samples were 
correctly identified as negative, thus, clinical specificity was 99.1%. On Biorad 
Dx, a lower number of sample could be used due to sample depletion. Clinical 
sensitivity was 97.4% (76 correctly identified out of 78 positive samples); 
whereas clinical specificity was 99.0% (102 correctly identified out of 103 
negative samples). According to the validation plan
10
, any result above 95% 
would have been considered adequate.  
 
3.3.3.2. Analytical sensitivity 
  
HPV 6 and 11 are the only two genotypes comprised in assay 2 panel, that need to 
be detected with a certain level of sensitivity, according to WHO requirements for 
genotyping tests. Thus far, therefore, they were the sole genotypes for which 
analytical sensitivity has been assessed. In order to do that, the WHO proficiency 
panel from 2013 was used (for panel composition see paragraph  4.2.6). Assay 2 
was able to correctly identify HPV 6 and 11 at a concentration of 50 GE/rx, which 
is a 10-fold lower concentration than that required by WHO.   
 
 
 
 
 
 
 
 
                                                             
10
  A document compiled before starting the validation process (for details see section 5). 
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4. MATERIALS AND METHODS 
 
4.1 DEVELOPMENT OF THE NEW VERSION OF THE 
REALQUALITY RI-HPV STAR DEVICE 
 
4.1.1. CERVICAL SWAB SAMPLES 
 
Cervical swab samples were provided from the Department of Pathology of the 
Central Hospital of Bolzano. The samples had been collected in the context of the 
follow up of patients with intraepithelial lesion or during ambulatory care visits 
for gynecologic condition. Cervical cells had been dispersed in PreservCyt 
transport medium in order to perform liquid based cytology. Cytological reports 
associated to the samples were provided as well. Such samples, if conserved at 4-
37 °C, are suitable for cytological analysis for up to 6 weeks after collection. 
Molecular analysis can be perform also several years after collection.   
 
4.1.2. ARTIFICIAL SAMPLES 
 
Artificial samples for HPV 6, 16, 18, 31, 33, 39, 51, 52, 53, 54, 59, 66, 68 and 73 
were prepared by diluting plasmids carrying the L1 sequence of the different HPV 
types in genomic background to mime clinical samples. Genomic DNA was 
extracted from HPV negative cervical samples.  
 
4.1.3. PCR / REAL-TIME PCR INSTRUMENTS 
 
End-point PCR was performed on the Applied Biosystems 2720 Thermal Cycler 
instrument (Applied Biosystems). Real-time PCR was performed on StepOnePlus 
Real-Time PCR System (Applied Biosystems) and on 7500 Fast Dx Real-Time 
PCR System (Applied Biosystems). Run files produced with StepOnePlus Real-
Time PCR System were analyzed with software version 2.2.2. Run files produced 
with 7500 Fast Dx Real-Time PCR System were analyzed with software version 
1.4. 
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4.1.4. DNA EXTRACTION  
 
Viral and genomic DNA from most cervical samples was extracted using the EZ1 
Advanced XL instrument (QIAGEN) and the EZ1 DSP Virus kit (QIAGEN), 
following manufacturer instructions. Manual DNA extraction was performed for a 
few samples using the QIAamp DNA mini Kit (QIAGEN), following 
manufacturer instruction.  
 
4.1.5. END-POINT PCR WITH PRIMER SET A 
 
Primer set A was selected from literature and, initially, used following the 
protocol provided in the original paper (64). In an attempt to eliminate aspecific 
PCR products, the original thermal profile was, later, modified as reported in table 
13: 
 
TEMPERATURE TIME CYCLES 
95 °C 10’ 1 
95 °C 30’’ 
5 43/44/45 °C 30’’ 
72 °C 45’’ 
95 °C 30’’ 
45 64 °C 30’’ 
72 °C 45’’ 
72 °C 10’ 1 
 
4.1.6. END POINT PCR WITH PRIMER SET B 
 
Primer set B was selected from literature and used following the protocol 
provided in the original paper (65) except for the thermal profile that was 
modified as reported in table 14: 
 
TEMPERATURE TIME CYCLES 
20 °C 5’ 1 
95 °C 5’ 1 
95 °C 30’’ 
45 50 °C 30’’ 
72 °C 30’’ 
72 °C 5’ 1 
Table 13. Modified thermal profile for end-point 
PCR with primer set A. three different annealing 
temperature for the first 5 cycles were tested. 
Table 14. Thermal used for end-point PCR with 
primer set B. 
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4.1.7. AGAROSE GEL ELECTROPHORESIS 
 
Agarose gel electrophoresis was performed by loading 10 µl of PCR product on a 
3% agarose gel. DNA-Marker pUC19/Msp I (Carl Roth) was employed (Fig. 36).  
 
 
 
 
 
 
 
 
 
 
 
4.1.8. NEW VERSION OF REALQUALITY RI-HPV STAR 
 
The new version of the REALQUALITY RI-HPV STAR device, as the old one, 
was based on Real-time PCR with intercalating dye and melting curve analysis. 
GP5+/GP6+ primers plus other primers selected from literature (primer set B 
(65)) were used for HPV amplification. TST was chosen as internal control (IC). 
The sequence of the primers used for TST amplification is covered by industrial 
secret and will not be disclosed. HPV primers were used at a higher concentration 
than TST primers in order to favor the amplification of the pathogen target. 
Precise primer concentrations are covered by industrial secret and will not be 
disclosed. Information on the employed mastermix and intercalating dye (named 
dye 1 in this writing) is covered by industrial secret and will not be disclosed. 
UNG (Uracil N-Glycosylase) enzyme was added to the mix in order to prevent 
carry-over contamination. The assay was meant to work on the StepOnePlus Real-
Time PCR System (Applied Biosystems).The thermal profile for the PCR reaction 
is summarized in table 15.  
 
 
Fig. 36. DNA-Marker pUC19/Msp I (Carl Roth) 
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TEMPERATURE TIME CYCLES 
50 °C 2’ 1 
95 °C 10’ 1 
95 °C 30’’ 
45 50 °C 30’’ 
72 °C 30’’ 
72 °C 5’ 1 
Dissociation step (default profile) 
 
A typical melting plot for a positive sample was showing at least three peaks, the 
first corresponding to primer dimers, the second to HPV, and the third to TST. In 
order to avoid misinterpretation of results a range for HPV positivity was defined 
(71-80 °C). 
 
4.1.9. NEW VERSION OF REALQUALITY RI-HPV STAR WITH HBB 
GENE AS INTERNAL CONTROL (discarded in the set up phase) 
 
The same conditions as in the selected new version of the REALQUALITY RI-
HPV STAR device (see paragraph 4.1.8) were used, except for that, instead of 
TST specific primers, HBB primers were used. The sequence of the primers used 
for HBB amplification is covered by industrial secret and will not be disclosed. 
 
4.1.10. NEW VERSION OF REALQUALITY RI-HPV STAR WITH DYE 2 
AS INTERCALATING DYE (discarded in the set up phase) 
 
The same conditions as in the selected new version of the REALQUALITY RI-
HPV STAR device (see paragraph 4.1.8) were used, except for that a different 
intercalating dye (named dye 2 in this writing) was employed. Information on 
intercalating dyes employed in AB ANALITICA devices is covered by industrial 
secret and will not be disclosed. 
 
 
 
Table 15. Thermal profile the of new version of the 
REALQUALITY RI-HPV STAR device. 
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4.1.11. AMPLIQUALITY HPV-TYPE 
 
The AMPLIQUALITY HPV-TYPE device (AB ANALITICA) allows genotyping 
of those samples that result positive after GP5+/G6+ PCR or a PCR performed 
using other primers targeting the same region in HPV genome. It is based on 
reverse line blot (RLB) technology. Basically, a membrane strip is spotted with 
probes reproducing a stretch of the HPV genome localized between GP5+ and 
GP6+ primers. Probes specific for 29 different genotypes (HPV 6, 11, 40, 42, 43, 
44, 54, 61, 70, 72, 81, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 
73, 82) are spotted at different heights on the strip to reproduce the band pattern 
showed in Fig. 37. An HPV universal band (HPV UNI)
11
 is generated as well, 
spotting together several degenerated probes. A band specific for an internal 
control gene (TST), used in some of the AB ANALITICA’s compatible kits is 
spotted above the UNI band and the HPV specific bands. Finally a “Control 
Staining” band is spotted at the top of the strip and represents a control for the 
colorimetric assay step. Once PCR has been performed, the amplification product 
is spread over the strip and let hybridize to the probes. Stringent washes allow the 
amplification product to be retained only where the complementary between the 
probes and the amplicons is perfect. The amplification products need to be 
                                                             
11  In case a sample is positive for an HPV type different from the 29 recognized by the device, the 
HPV UNI BAND will still signal that the sample is positive. 
Fig. 37. Band pattern of the AMPLIQUALITY 
HPV-TYPE strip. Probes for 29 HPV genotypes 
are spotted at different  heights. A HPV 
universal band, a TST specific band and a 
Control Staining band are spotted as well at the 
top of the strip.  
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biotinylated for the following step to work. This can be achieved either by using 
biotinylated primers or by linking biotin to the amplicons after the amplification 
step. The biotinylation is necessary to perform a colorimetric assay, based on 
streptavidin conjugated alkaline phosphatase and NBT/BCIP substrate, which 
produces a dark band were the amplicons have hybridized (Fig. 38).  
The device was used, according to manufacturer instruction, to genotype samples 
that resulted positive after amplification with the new version of the 
REALQUALITY RI-HPV STAR device. 
 
 
 
 
 
 
 
 
4.1.12. AMPLIQUALITY TYPE-EXPRESS V. 2.0 (REFERENCE 
METHOD) 
 
AMPLIQUALITY TYPE-EXPRESS v. 2.0 (AB ANALITICA) was used, 
following manufacturer instructions, to genotype all sample that were later used to 
set up the reaction for the new version of the REALQUALITY RI-HPV STAR 
device and to verify its performance. This product is based on end-point PCR 
targeting the L1 region of HPV genome, followed by reverse line blot. It 
recognizes 29 different HPV types (HPV 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, 
16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82).   
 
 
 
 
 
 
 
Fig. 38. Cartoon representing a RLB 
colorimetric assay based on biotin 
labeled amplicons, streptavidin 
coniugated alkaline phosphatese and 
NBT/BCIP substrate. 
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4.2. DEVELOPMENT AND VALIDATION OF THE 
REALQUALITY RQ-HPV HR MULTIPLEX AND THE 
REALQUALITY RQ-HPV HR/LR MULTIPLEX DEVICES 
 
4.2.1. CERVICAL SWAB SAMPLES 
 
See paragraph 4.1.1. 
 
4.2.2. URETHRAL, ANAL, FORESKIN AND VAGINAL BIOPSIES 
 
Urethral, anal, foreskin and vaginal biopsies were purchased from Cerba 
Specimen Services (Saint Ouen l’Aumône, France).  
 
4.2.3. URINE SAMPLES 
 
Urine samples were purchased from Cerba Specimen Services (Saint Ouen 
l’Aumône, France) 
 
4.2.4. DNA EXTRACTS FROM ORAL, URETHRAL AND VAGINAL 
SWAB SAMPLES AND FROM VAGINAL DISCHARGE SAMPLES 
 
DNA extracts from oral, urethral and vaginal swab samples and from vaginal 
discharge samples were provided from the Department of Pathology “Gaetano 
Barresi” of the University of Messina (A.O.U. Policlinico G. Martino, Messina). 
 
4.2.5. ARTIFICIAL SAMPLES 
 
Artificial samples for HPV 16 and 18 were prepared by diluting plasmids carrying 
a fragment of the respective E6/E7 sequence in genomic background to mime 
clinical samples. Genomic DNA was extracted from HPV negative cervical 
samples. Plasmids were produced by GC cloning (Lucigen) of PCR fragments. 
Artificial samples positive for other pathogens were either Acrometrix controls 
(Life Technologies) or Vircell controls (Vircell Microbiologists).  
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 4.2.6. GLOBAL HPV LABNET 2013 HPV DNA GENOTYPING 
PROFICIENCY PANEL 
 
AB ANALITICA received the panel from the WHO HPV LabNet in 2013 in the 
context of an international proficiency study for HPV genotyping test. The panel 
composition is summarized in table XX. 
 
WHO SAMPLE GENOTYPE 
CONCENTRATION 
(GE/5μl) 
1 58 50 
2 18 50 
3 39, 45, 52, 56, 68b 500 
4 33 50 
5 52 500 
6 68b 500 
7 6 500 
8 39 50 
9 66 500 
10 35, 59, 66, 68a 500 
11 16 50 
12 31 50 
13 52 50 
14 68a 500 
15 negative 0 
16 51 500 
17 31 500 
18 11, 31, 33, 58 500 
19 56 50 
20 68b 50 
21 35, 59, 66, 68a 50 
22 6 50 
23 45 50 
24 59 50 
25 39, 45, 52, 56, 68b 50 
26 18 5 
27 35 50 
28 59 500 
29 6, 16, 18, 51 500 
30 16 5 
31 35 500 
32 58 500 
33 11, 31, 33, 58 50 
34 11 50 
35 45 500 
36 66 50 
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WHO SAMPLE GENOTYPE 
CONCENTRATION 
(GE/5μl) 
37 6, 16, 18, 51 50 
38 11 500 
39 33 500 
40 39 500 
41 56 500 
42 68a 50 
43 51 50 
A none 0 
B 16 2500 
C 16 25 
 
Table 16. Composition of the WHO proficiency panel from 2013. 
 
 
4.2.7. QCMD 2014 HUMAN PAPILLOMAVIRUS DNA EQA PANEL 
 
AB ANALITICA received the QCMD panel in the context of the QCMD 2014 
Human Papillomavirus DNA EQA Programme. The panel had been developed to 
assess the proficiency of laboratories in the detection and genotyping of HPV. Its 
composition is summarized in table 17. 
 
SAMPLE MATRIX CONTENT STATUS TYPE 
HPV14-02 
Pre servCyt + 
BSM 
HPV16 (Caski) Positive Core 
HPV14-06 
Pre servCyt + 
BSM 
HPV18 (Hela) Positive Core 
HPV14-01 
Pre servCyt + 
BSM 
HPV45 (CC10b) Positive Core 
HPV14-09 
Pre servCyt + 
BSM 
HPV16 /18 (Caski/Hela) Positive Core 
HPV14-10 
Pre servCyt + 
BSM 
Lo w Vi r al Lo ad HPV16 
(SiHa) 
Positive Educational 
HPV14-08 
Pre servCyt + 
BSM 
HPV5 1&5 2 (clinical sample) Positive Educational 
HPV14-04 
Pre servCyt + 
BSM 
HPV5 2 &5 6 (clinical sample) Positive Educational 
HPV14-07 
Pre servCyt + 
BSM 
HPV5 4&5 6 (clinical sample) Positive Educational 
HPV14-03 
Pre servCyt + 
BSM 
HPV Negative (BSM) Negative Core 
HPV14-05 
Pre servCyt + 
BSM 
HPV Negative (BSM) Negative Core 
 
Table 17. Composition of the QCMD panel from 2014. 
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4.2.8. PCR / REAL-TIME PCR INSTRUMENTS 
 
End-point PCR was performed on the Applied Biosystems 2720 Thermal Cycler 
instrument (Applied Biosystems). Real-time PCR was performed on 7500 Fast Dx 
Real-Time PCR System (Applied Biosystems) and on Dx Real-Time System 
(BIO-RAD). Run files produced with 7500 Fast Dx Real-Time PCR System were 
analyzed with software version 1.4. Run files analysed with Dx Real-Time 
System were analyzed with software version 1.7. 
 
4.2.9. DNA EXTRACTION  
 
Viral and genomic DNA from cervical samples was extracted using the 
GENEQUALITY X120 instrument (AB NALITICA) and the GENEQUALITY 
X120 Pathogen kit (AB ANALITICA), following manufacturer instructions. 
Biopsies were pre-treated with proteinase K before performing DNA extraction 
with the EZ1 Advanced XL instrument (QIAGEN) and the EZ1 DSP Virus kit 
(QIAGEN), following manufacturer instructions.  
Urine samples were concentrated before extraction with the EZ1 Advanced XL 
instrument (QIAGEN) and the EZ1 DSP Virus kit (QIAGEN), following 
manufacturer instructions. 
 
4.2.10. DESIGN OF GENOTYPE SPECIFIC PRIMERS AND PROBES 
 
Primers and probes had to be genotype specific, thus, sequence relatedness issues 
had to be considered before selecting candidate oligos. The E6/E7 sequences of 
32 HPV types (the 22 target genotypes plus other 10 low risk types) were 
retrieved from GenBank. Clustal Omega was used to align the sequences and 
generate a phylogenetic tree (Fig. 39). This tree was used as a guide to predict 
which types could have been, more likely, the cause of aspecific PCR products. 
For example, the design of HPV 18 primers and probe was done looking at the 
aligned sequences of HPV 18 and HPV 45, the closest genotype in the 
phylogenetic tree, in order to select DNA segments carrying mismatches for the 
non-specific sequence.  
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Fig. 39. Phylogenetic tree based on the E6/E7 sequences of 32 HPV genotypes (Clustal Omega). 
 
Also, before starting the acutal design, several papers providing primer and probe 
sequences targeting the HPV E6/E7 region were consulted. Genotype specific 
primers form the literature tended to be concentrated in delimited portions of the 
E6/E7 sequence, suggesting they might have been favorable. When possible, 
primers and probe were designed in those regions. In Fig. 40, the E6/E7 sequence 
of HPV 18 is reported. Primers from four papers (66-69), all localizing in the 
lower portion of the sequence, are highlighted in different colors.  
Another thing that had to be taken into account was that the thermal profile of the 
new PCR reactions had to be the same of all the other devices targeting infective 
pathogens in AB ANALITCA’s catalogue (table 18). Primers and probe were all 
designed without the help of designing tools, however, to check whether the 
annealing temperature was correct, Primer3 was used.  
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Fig. 40. The E6/E7 sequence of HPV 18 is reported with primers form four papers highlighted in different 
colors (light green and light blue (66), yellow (67), grey (68), dark green(69)). In case of overlapping primers 
the color of the upstream primer is retain and the overlapping fragment is in bold.  
 
TEMPERATURE TIME CYCLES 
50 °C 2’ 1 
95 °C 10’ 1 
95 °C 15’’ 
45 
60 °C 1’ 
 
Once selected a candidate primer or a probe, analytical specificity was evaluated 
in silico by BLAST analysis. Firstly, its sequence was aligned against the specific 
target organism (e.g. taxid: 333761 for HPV 18) to check whether there were 
genotype variants carrying mismatches in that stretch of DNA. If there was more 
than one mismatch for a group of variants or, only for primers, if a mismatch was 
located at the 3’end of the sequence, within the fourth nucleotide, then the 
oligonucleotide was discarded. If the first step went ok, the oligonucletide was 
blasted against all alphapapillomaviruses excluding the specific target (e.g. 
taxid:333750, excluded taxid: 333761). To be considered ok, the oligonucleotide 
had to align to other HPV types sequences with at least five dispersed mismatches 
or, only in case of primers, with at least three mismatches at the 3’end, within the 
fifth nucleotide. If ok, it was aligned against all organisms, excluding 
alphapapillomaviruse, and against human genomic DNA to check for other 
possible cross-reactivity phenomenon. The “five mismatch / three mismatch at the 
3’end rule” was applied also here. If alignments with other organisms had 
occurred, they would have been taken into account only if those species could 
Table 18. Thermal profile of AB ANALITICA’s 
devices for the detection of infective pathogens. 
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have infected the same districts as HPV; however, such a circumstance never 
presented. 
 
4.2.11. VERIFYING PRIMER ANALYTICAL SPECIFICITY: SIMPLEX 
REAL-TIME PCR WITH INTERCALATING DYE 
 
For some genotypes, different primer pairs were ordered and tested in simplex by 
Real-time PCR with intercalating dye to select the best performing one, before 
ordering the respective probe. Information on primer/probe sequences, on 
primer/probe concentration and on the employed mastermix and intercalating dye 
is covered by industrial secret and will not be disclosed. The thermal profile was 
the same used in the final version of assay 1 and 2 (see paragraph 4.2.14). 
 
4.2.12. VERIFYING PRIMER/PROBE ANALYTICAL SPECIFICITY: 
SIMPLEX REAL-TIME PCR 
 
To check if primer pairs and probes were specific for the target genotypes, 
simplex Real-time PCR was performed. Information on primer/probe sequences, 
on primer/probe concentration and on the employed mastermix is covered by 
industrial secret and will not be disclosed. The thermal profile was the same used 
in the final version of assay 1 and 2 (see paragraph 4.2.15). 
 
4.2.13. PARTIAL MULTIPLEX REAL-TIME PCR 
 
Partial multiplex Real-time mixes were assembled by adding new target specific 
primers and probes two by two. The partial mixes were tested on known HPV 
positive and negative clinical samples in order to check whether the newly added 
oligos could interfere with the others. Information on primer/probe sequences, on 
primer/probe concentration and on the employed mastermix is covered by 
industrial secret and will not be disclosed. The thermal profile is the same used in 
the final version of assay 1 and 2 (see paragraph 4.2.15). 
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4.2.14. AGAROSE GEL ELECTROPHORESIS 
 
 
 
 
 
 
 
 
Agarose gel electrophoresis was performed by loading 10 µl of PCR product on a 
3% agarose gel. 100 bp DNA Ladder ready-to-use (Bioron) was employed (Fig. 
41).  
 
 
4.2.15. ASSAY 1 REAL-TIME PCR 
 
Assay 1 Real-time PCR includes primers and probes for HPV 16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, 59, 66 and 68 as well as a primer pair and a probe for HBB. 
It is a four fluorophore Real-time reaction. The correspondence between targets 
and fluorophors is summarized in table 19. 
 
Assay JOE CY5 FAM ROX 
1 HPV 16 HPV 18  
HPV 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 66, 68  
HBB 
(Internal control) 
 
Table 19. Correspondence between targets and fluorophors for assay 1. 
 
Information on primer/probe sequences, on primer/probe concentration and on the 
employed mastermix is covered by industrial secret and will not be disclosed. 
UNG (Uracil N-Glycosylase) enzyme was added to the mix in order to prevent 
carry-over contamination. The thermal profile is summarized in table 20. 
Assay 1 corresponds to the REALQUALITY RQ-HPV HR MULTIPLEX device. 
 
 
Fig. 41. 100 bp DNA Ladder ready-to-use (Bioron) 
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TEMPERATURE TIME CYCLES 
50 °C 2’ 1 
95 °C 10’ 1 
95 °C 15’’ 
45 
60 °C 1’ 
 
 
4.2.16. ASSAY 2 REAL-TIME PCR 
 
Assay 1 Real-time PCR includes primers and probes for HPV 6, 11, 26, 53, 67, 
70, 73 and 82 as well as a primer pair and a probe for HBB. It is a four 
fluorophore Real-time reaction. The correspondence between targets and 
fluorophors is summarized in table 21. 
 
Assay JOE CY5 FAM ROX 
2 
HPV 6 
(low risk) 
HPV 11  
(low risk) 
HPV 26, 53, 67, 70, 73, 82 
(probabile high risk) 
HBB 
(internal control) 
 
Table 21. Correspondence between targets and fluorophors for assay 2. 
 
Information on primer/probe sequences, on primer/probe concentration and on the 
employed mastermix is covered by industrial secret and will not be disclosed. 
UNG (Uracil N-Glycosylase) enzyme was added to the mix in order to prevent 
carry-over contamination. The thermal profile is the same used in the final version 
of assay 1 (see paragraph 4.2.15). 
Assay 2, if associated to assay 1, provides the final user with a complete panel for 
HPV investigation. Assay 1 and 2, together, correspond to the REALQUALITY 
RQ-HPV HR/LR MULTIPLEX device. 
 
4.2.17. A, B, C, D, E REAL-TIME REACTIONS  
 
A, B, C, D, E Real-time reactions were used to verify the presence of an “assay 1 
FAM genotype
12” in samples that produced unexpected FAM signals during assay 
                                                             
12  HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68. 
 Table 20. Thermal profile of assay 1. 
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1 validation
13
. All reactions contained the same primers as assay 1, but only a 
subset of probes. A scheme of how probes were allocated among the five 
reactions is represented in Fig. 42.  
 
 
 
 
 
 
 
 
If present in mono-infection, each FAM genotype gives an univocal pattern of 
positivity among the five mixes (table 22). 
 
GENOTYPE MIX 
31 A, D 
33 A, D, E 
35 A, E 
39 A 
45 B, D 
51 B, D, E 
52 B, E 
56 E 
58 C, D 
59 C, D, E 
66 C, E 
68 E 
 
Table 22. Pattern of positivity in mixes A, B, C, D, E for the 12 FAM genotypes of assay 1. 
 
Information on primer/probe sequences, on primer/probe concentration and on the 
employed mastermix is covered by industrial secret and will not be disclosed. 
 
 
                                                             
13 Samples that were not positive for any of the “assay 1 FAM genotypes”, according to the 
reference method (HPV-TYPE EXPRESS v. 3.0), but produced signals in the FAM channel, when 
tested with assay 1. 
Fig. 42. Scheme representing how assay 1 FAM probes 
were allocated among mixes A, B, C, D and E. 
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4.2.18. F, G, H, I REAL-TIME REACTIONS  
 
F, G, H, I Real-time reactions were used to verify the presence of an “assay 2 
FAM genotype
14” in samples that produced unexpected FAM signals during assay 
2 validation
15
. All reactions contained the same primers as assay 2, but only a 
subset of probes. A scheme of how probes were allocated among the four 
reactions is represented in Fig. 43. 
 
 
 
 
 
 
If present in mono-infection, each FAM genotype gives an univocal pattern of 
positivity among the five mixes (table 23). 
 
GENOTYPE MIX 
26 F, I 
53 F 
67 G, I 
70 G 
73 H, I 
82 H 
 
Table 23. Pattern of positivity in mixes F, G, H, I for the 6 FAM genotypes of assay 2. 
 
Information on primer/probe sequences, on primer/probe concentration and on the 
employed mastermix is covered by industrial secret and will not be disclosed. 
 
 
 
                                                             
14  HPV 26, 53, 67, 70, 73, 82. 
15 Samples that were not positive for any of the “assay 2 FAM genotypes”, according to the 
reference method (HPV-TYPE EXPRESS v. 3.0), but produced signals in the FAM channel, when 
tested with assay 2. 
Fig. 43. Scheme representing how assay 2 FAM probes 
were allocated among mixes F, G, H, and I. 
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4.2.19. END-POINT PCR AND SEQUENCING OF DISCORDANT 
SAMPLES 
 
Samples used for validating assay 1 and 2 were also tested with a reference 
method (AMPLIQUALITY HPV-TYPE EXPRESS, v. 3.0; AB ANALITICA). In 
case of discordant results, sequencing was used to confirm the genotype 
composition of the sample.  
In case assay 1 or assay 2 detected a genotype not detected by the reference 
method, simplex end-point PCR was performed, with the primers for the genotype 
of interest
16
 used in assay 1 or assay 2 reactions. The PCR product was then sent 
to BMR Genomics for sequencing. In case the reference method detected a 
genotype not detected by assay 1 or assay 2, the primers specific for the genotype 
of interest, employed in the reference method reaction, were used to perform 
simplex end-point PCR on the discordant sample. The PCR product was then sent 
to BMR Genomics for sequencing.  
Information on primer sequences, on primer concentration and on the employed 
mastermix is covered by industrial secret and will not be disclosed. 
 
4.2.20. PROBIT ANALYSIS 
 
Probit analysis was used to determine the limit of detection of assay 1 for HPV 16 
and HPV 18. Artificial samples containing the genotype of interest at five 
different concentrations (7.5 – 5 – 2.5 – 1.25 – 0.5 GE/rx) were used. To produce 
a sufficient amount of data for the probit model, each concentration was tested in 
8 replicates for 3 consecutive runs. Each run output was converted to binary 
language, 1 representing a successful amplification and 0 representing a failed 
amplification. Table 24 is an example of a possible run output. Data were 
analyzed with R Software (p set to 0.05). 
 
 
 
                                                             
16  In case of FAM unexpected signal the genotype had to be first identified with mixes A, B, C, D, 
E or mixes F, G, H, I. 
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REPLICA
TE 1 
REPLICA
TE 2 
REPLICA
TE 3 
REPLICA
TE 4 
REPLICA
TE 5 
REPLICA
TE 6 
REPLICA
TE 7 
REPLICA
TE 8 
7.5 
GE/
rx 
1 1 1 1 1 1 1 1 
5.0 
GE/
rx 
1 1 1 1 1 1 1 1 
2.5 
GE/
rx 
1 1 0 0 1 1 1 1 
1.25 
GE/
rx 
0 1 0 1 0 0 1 1 
0.5 
GE/
rx 
1 0 0 0 1 0 1 0 
 
Table 24. Run output converted to binary language for probit analysis (1 = successful 
amplification; 0 = failed amplification). 
 
4.2.21. COEFFICIENT OF VARIATION 
 
The Coefficient of Variation (CV) is a standardized measure of dispersion of a 
probability distribution or a frequency distribution. It is defined as the ratio of the 
standard deviation σ to the mean μ, but is often presented as the given ratio 
multiplied by 100. In this work it was used to give a measure of intra- and inter-
assay variability of assay 1 and was calculated as follows:    
 
CV = ( 
       
 
 ) 
 
4.2.22. INTRA-ASSAY VARIABILITY FOR ASSAY 1 
 
To measure intra-assay variability for assay 1, 15 samples were used, each 
positive for one of the following genotypes detected by assay 1: HPV 16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68a and 68b. Each sample was amplified in 
eight replicates in a single run. The CVs for the Ct (Threshold Cycle) values 
produced by each genotype were then calculated. 
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4.2.23. INTER-ASSAY VARIABILITY FOR ASSAY 1 
 
To measure inter-assay variability for assay 1, 15 samples were used, each 
positive for one of the following genotypes detected by assay 1: HPV 16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68a and 68b. Each sample was amplified in 
three consecutive runs. The CVs for the Ct (Threshold Cycle) values produced by 
each genotype were then calculated. 
 
4.2.24. HPV TYPE-EXPRESS V. 3.0 (REFERENCE METHOD) 
 
AMPLIQUALITY TYPE-EXPRESS v. 3.0 (AB ANALITICA) was used, 
following manufacturer instructions, to genotype all sample that were later used to 
set up the reactions for assay 1 and assay 2 and verify their performance. This 
product is based on end-point PCR targeting the L1 region of HPV genome, 
followed by reverse line blot. It recognizes 40 different HPV types (HPV 6, 11, 
16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 
64, 66, 67, 68a, 68b, 69, 70, 71, 72, 73, 81, 82, 83, 84, 87, 89 and 90).  
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5. DISCUSSION 
 
In the first part of my PhD, I worked on the prototype new version of a product 
recently developed at AB ANALITICA, the REALQUALITY RI-HPV STAR 
device. My task was to bring the original device to an higher level of analytical 
sensitivity for certain HPV genotypes as required by the World Health 
Organization.  
The primers used in the original reaction mix were GP5+/GP6+ primers. These 
oligos are among those developed at the beginning of the HPV detection era. They 
target the most conserved region in HPV genome, i.e. L1, and are capable of 
detecting most HPV types in aggregate. However, the analytical sensitivity they 
provide is not equal for all the detected genotypes (62) and their performance was 
not in compliance with WHO requirements for genotyping tests.  
First of all, the primer composition in the reaction mix was modified by adding 
other primers to the original pair. A multiple primer reaction required employing 
specific reagents and, at the end, the whole set up of the assay had to be modified. 
The occasion was used to also improve an ergonomic aspect and amplify the 
target pathogen and the internal control gene in multiplex instead of running two 
separate reaction as in the original assay. 
Higher analytical sensitivity was achieved, but at the expense of robustness. 
Discrimination between positive and negative sample was based on melting curve 
analysis with intercalating dye technology. The presence of a melting peak in a 
defined range of melting temperature would have meant the sample was HPV 
positive. The genotype was than to be determine by RLB with the 
AMPLIQUALITY HPV-TYPE device. 
Unfortunately, primer dimers related problems emerged. The corresponding 
melting peaks, in most cases, were located before the HPV positivity range. 
However, while evaluating clinical specificity on HPV negative samples, I 
randomly observed primer dimers peaks with shoulders invading the HPV 
positivity range. The Real-time PCR instrument never recognized those shoulders 
as actual peaks, nevertheless, they were clearly visible by eye. First of all, such an 
output could have generated confusion in the final user. Secondly it was not 
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possible to foresee whether the problem could have exacerbated under standard 
production conditions, that require frequent changes in the reagent batches used, 
and whether, at a certain point, the Real-time PCR instrument would have started 
to recognize those shoulders as real peaks. I tested different reaction conditions in 
order to solve the problem, with no improvements. On that premise, abandoning 
the project was considered the only feasible possibility, as the risk of releasing on 
the market a product generating an uncontrollable number of false positive results 
was not acceptable.  
The use of intercalating dyes for Real-time PCR and melting curve analyses is 
convenient and cost effective, as it allows to detect multiple targets without the 
need to produce or order specific probes. On the other hand, with this technology, 
both specific and aspecific signals are visualized in the Real-time and melting 
plots. In a reaction with multiple primers, like that of the new version of the 
REALQUALITY RI-HPV STAR device, the generation of PCR by-products, 
such as primer dimers, was a highly probable event and, as expected, occurred 
with nearly every tested sample. The device could still have worked efficiently if 
the HPV positivity range had remained uninvolved, but this was not the case. 
Probably, melting curve analysis employing an intercalating dye did not represent 
the best choice for the intended application due to the above mentioned intrinsic 
limitations. 
 
In the second part of my PhD, I worked at the design, development and validation 
of two new assays for HPV detection which also provide partial genotyping 
information. In this occasion, it was decided to abandon the RLB technology, 
which can result cumbersome and time consuming for the final user, and rely only 
on Real-time PCR, which, on the contrary, is a very popular technology in the 
field of diagnostics, as it is simple and does not require too much hand-on time for 
the final user. Melting curve analysis, however, was not considered as an option, 
this time, due to the problems experienced with the previous project. Instead, 
Real-time PCR with target specific primers and TaqMan fluorescent probes was 
employed.  
Another significant difference with respect to the previous project is that the target 
region of the new devices is E6/E7 instead of L1. This choice was due to both 
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commercial and practical reasons. A key event in HPV-induced carcinogenesis is 
the integration of HPV genome in one of the host chromosomes, which can, in 
some rare cases, lead to the loss of L1, but not of E6/E7 (50). Since residual 
integrated HPV DNA can, ultimately, be the only form of viral DNA present in 
infected cells, devices based on L1 detection might miss a small, but yet 
significant, portion of infections, whereas E6/E7 targeting devices will not (63). 
Targeting E6/E7, thus, represents a strong marketing feature, especially 
considering that devices from most competitors target L1(11). On the practical 
side, being L1 sequence the most conserved in HPV genome, the design of type 
specific primers and probes in that region would probably have been much more 
difficult.   
The two assay were design in order to target all the HPV genotypes necessary to 
ensure compliance with the WHO requirements for a genotyping assay (i.e. HPV 
6, 11, 16, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) plus other possible high 
risk genotypes, according to IARC classification (31). 
Once the reactions for the two assays were set up, they had to be validated. 320 
samples were employed during the validation of the assays targeting HPV 16, 18, 
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68 (assay 1), whereas 192 samples 
were used to validate the assay targeting HPV 6, 11, 26, 53, 67, 70, 73 and 82 
(assay 2). Both assays were validated on two instruments for Real-time PCR, ABI 
7500 Fast Dx and Biorad Dx. Clinical sensitivity and specificity for both assays 
on both instruments resulted adequate, being above 95%. The 95% cut-off is not a 
universally established threshold for clinical sensitivity and specificity assessment 
for devices of this kind, however, is not arbitrary. Before starting the validation 
process in an industrial context, a validation plan has to be complied in which 
criteria for acceptable performance are stated. The 95% cut-off was established on 
the base of two main considerations: 1) all methods for HPV detection differ in 
the analytical sensitivity for different HPV types, thus, complete concordance on 
clinical samples is not a probable occurrence, especially when testing samples at 
limit concentrations; 2) competitors declare clinical sensitivity and specificity 
performance in the 95-99% range. 
Data from the validation set were also used to calculate genotype concordance 
between assay 1 and the reference method. This resulted to be around 90%. Again 
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different analytical sensitivity for specific genotypes accounts for different results 
from the two methods. Moreover, for those cases in which assay 1 detected the 
presence of a high risk genotype (later confirmed by sequencing), while the 
reference method only detected low risk genotype or no HPVs at all, the result 
could be attributed to the fact that the reference method targets L1 and, therefore, 
can miss HPV infection in case of complete integration of viral genome with 
disruption of the L1 ORF. However, being those samples all associated to 
negative or ASCUS cytological reports and being complete integration associated 
to late stadiums of cancer progression, this hypothesis does not seem to fit 
circumstances.  
As for analytical sensitivity, compliance with the WHO requirements was tested 
using the WHO proficiency panel from 2013. Not only all genotypes (HPV 6, 11, 
16, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) were detected at the required 
limit concentration, but, also, they were correctly identified at a 10-fold lower 
concentration. For HPV 16 and 18, the two most dangerous HPV types, the exact 
LOD was established with probit analysis. The results confirmed that the 
analytical sensitivity for those genotypes is one order of magnitude higher than 
that required by WHO.  
WHO proficiency panels are provided in the context of international proficiency 
studies. When the WHO release a panel, there is a window of time for result 
submission, then the panel composition is reveled and official responses on assay 
performance are sent to study participants. When I tested the two devices on the 
WHO panel from 2013, it was too late to submit the results. The panel for 2014 is 
not available yet due to production issues, however, as soon as it will, both assays 
will be tested on the new panel and results submitted in order to receive an official 
response.  
In 2014, however, AB ANALITCA participated to another external quality 
assessment program, i.e. the QCMD 2014 Human Papillomavirus DNA EQA 
Program. Only assay 1 was ready by the time results could be submitted, thus, 
was the sole to be tested with the QCMD panel. This panel comprises both core 
samples, i.e. samples that have to be detected by a device to be declared 
proficient, and educational samples, i.e. samples that provide participants with 
additional information on their assay sensitivity. Assay 1 was capable to correctly 
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identify all core samples. Only one of the educational samples was erroneously 
identified as HPV negative, while being a low viral load HPV 16 positive sample, 
instead. It has to be outlined, however, that, as the QCMD referred, this sample 
did not result positive also when analyzed by an external testing laboratory using 
the Cobas HPV assay (ROCHE) and the HC2 assay (QIAGEN), both FDA 
approved and CE IVD marked methods.  
Other performance parameters, such as analytical specificity and repeatability 
have already been assessed only for assay 1. Assessment for assay 2 is ongoing.  
As for the analytical specificity of assay 1, both low risk HPV positive samples 
and samples positive for other pathogen were tested. Samples of the latter group 
all resulted negative except for one sample that was later demonstrated to actually 
contain high risk HPV DNA. Of the 54 samples positive for low risk HPV types, 
two produced unexpected FAM signals, with late Ct values, only on the ABI 7500 
Fast Dx instrument. The presence of high risk genotypes, though, could not be 
demonstrated as subsequent amplifications finalized to sequencing did not 
produced any PCR product. According to the reference method, 
AMPLIQUALITY HPV-TYPE EXPRESS v. 3.0, one of the two samples was 
positive for HPV 6 and 87, the other for HPV 40 and 84. Cross-reactivity with 
these genotypes, however, can be excluded as other samples positive for the same 
types did not produce any amplification signal. HPV 6 samples, in particular, are 
also comprised in the WHO panel and, when amplified with assay 1, did not 
generate unexpected signals. A possible explanation to these result is that those 
two samples were actually positive for an high risk HPV type, but its 
concentration was below the limit of detection of the reference method and close 
the limit of detection of assay 1 that, therefore, produced non-reproducible results 
among instruments and in subsequent amplifications. On the base of these 
considerations, the analytical specificity of assay 1 was regarded as adequate. 
As for repeatability, intra- and inter-assay coefficient of variation for all HPVs 
targeted by assay 1 were calculated and all resulted below 1.5%, proving that 
assay 1 is highly repeatable. 
In conclusion assay 1 performance is largely in compliance with WHO 
requirements and with the acceptability criteria established in the validation plan, 
thus, this assay will be soon commercialized under the name REALQUALITY 
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HPV-HR MULTIPLEX. As for assay 2, some performance parameters have still 
to be assessed, but initial data are promising. This second assay, if associated to 
assay 1, provides the final user with a complete panel for HPV investigation. For 
this reason assay 1 and 2, together, will be proposed, as an alternative product, 
under the name REALQUALITY RQ-HPV HR/LR MULTIPLEX. 
Both products will need CE IVD marking and FDA approval as AB ANALITICA 
intends to sell them in Europe and US. The combined product will also be 
submitted for CFDA (Chinese Food and Drug Administration) approval with a 
slight modification to the panel of detected genotypes. In brief, assay 1 will 
remain the same, whereas assay 2 will allow the pooled detection of HPV 6 and 
11 (most relevant low risk types) in the Cy5 channel, the pooled detection of HPV 
26, 53, 67, 70, 73 and 82 (possible high risk types) in the FAM channel and the 
pooled detection of HPV 40, 42, 43, 44, 55 and 83 (low risk types) in the JOE 
channel. The Chinese panel of detectable genotypes was design taking into 
consideration the suggestions from one of AB ANALITICA’s Chinese 
distributors. The assessment of the performance of the Chinese product is 
ongoing. 
As mentioned several times, compliance with WHO requirements for HPV 
genotyping assays has been a pivotal aspect of my whole work; however, assay 1 
would also make a good screening device as it is high risk HPV specific and 
allows fast analysis of multiple samples. For these reasons, AB ANALITICA is 
considering to validate it for the scope of screening, following the instruction 
provided in the landmark paper written by Meijer et al. (61). In order to be 
considered adequate for screening, assay 1 should be tested on at least 60 
histologically confirmed CIN 2+
17
 positive samples and at least 800 histologically 
confirmed CIN 2+ negative samples. All samples should have been previously 
tested with an already approved screening method (e.g. HC2). Sensitivity and 
specificity of assay 1 with respect to the reference method should be of at least 
90% and 98% respectively.  
Beside cervical cancer, HPV seems to be responsible for a considerable 
proportion (40%) of head and neck cancers (27). While validating assay 1, also 30 
oral swabs samples were tested. Three of these samples resulted positive for an 
                                                             
17
 CIN2+ category comprises CIN2, CIN3 and cancer. 
102 
 
high risk HPV type with both assay 1 and the reference method (already validated 
on this kind of specimens). All the other samples resulted negative with both 
devices. This result indicates that assay 1 could be adequate to assess HPV 
positivity also in oral swabs, however a higher number of positive sample will 
have to be tested in order to confirm the result. 
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APPENDIX 
 
SUMMARY 
 
The subject of this dissertation is the work I carried out at AB ANALITICA s.r.l. 
in the context of a doctoral program based on higher apprenticeship, an innovative 
form of PhD aiming at reducing the distance between academia and business. 
 
In the first part of my PhD I worked on the new version of a product for HPV 
detection, recently developed at AB ANALITICA: the REALQUALITY RI-HPV 
STAR device. My task was to bring the original device to a higher level of 
analytical sensitivity for certain HPV genotypes as required by the World Health 
Organization (WHO).  
This device was based on Real-time PCR and melting curve analysis with 
intercalating dye technology. The primers used in the original reaction mix were 
GP5+/GP6+ primers. These primers are capable of detecting most HPV types in 
aggregate. However, the analytical sensitivity they provide is not equal for all the 
detected genotypes and their performance was not in compliance with WHO 
requirements for genotyping tests. Thus, first of all, the primer composition in the 
reaction mix was modified by adding other primers to the original pair. A multiple 
primer reaction required employing specific reagents and, at the end, the whole set 
up of the assay had to be modified. The occasion was used to also improve an 
ergonomic aspect and amplify the target pathogen and the internal control gene in 
multiplex instead of running two separate reactions as in the original assay. 
Higher analytical sensitivity was achieved, but primer dimers related issues 
emerged, which could have impaired the correct interpretation of the assay results, 
and the project was abandoned.  
 
In the second part of my PhD, I worked at the design, development and validation 
of two new assays for HPV detection, based on Real-time PCR with target 
specific primers and TaqMan fluorescent probes. 
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The HPV types detected by the first of the two assays are the 14 most common 
high risk types, i.e. HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. 
The second assay detects the two most common low risk types, i.e. HPV 6, 11, as 
well as other possible high risk types, i.e. HPV 26, 53, 67, 70, 73 and 82.  
Assay 1 has already been validated and its performance resulted largely in 
compliance with WHO requirements and with the acceptability criteria 
established in the validation plan. This assay, therefore, is ready to be 
commercialized under the name REALQUALITY RQ-HPV HR MULTIPLEX.  
As for assay 2, some performance parameters have still to be assessed; however, 
initial data are promising. This second assay, if associated to assay 1, provides the 
final user with a complete panel for HPV investigation. The two assays combined, 
therefore, will be soon proposed, as an alternative product, under the name 
REALQUALITY RQ-HPV HR/LR MULTIPLEX. 
 
 
RIASSUNTO 
 
Oggetto di questa tesi è il lavoro svolto presso l’azienda AB ANALITICA s.r.l. 
nell’ambito di un Dottorato di Ricerca in Alto Apprendistato, una forma 
innovativa di dottorato che mira ad avvicinare il mondo dell’università a quello 
del lavoro. 
 
Nella prima parte del mio percorso di dottorato ho lavorato ad un progetto che 
aveva come obbiettivo lo sviluppo di una nuova versione del prodotto 
REALQUALITY RI-HPV STAR, un dispositivo per la rilevazione dell’HPV 
commercializzato da AB ANALITICA. La nuova versione doveva innanzitutto 
corrispondere ai criteri di sensibilità analitica definiti dalla World Health 
Organization (WHO) per i dispositivi di genotipizzazione dell’HPV. 
La tecnologia su cui si basa il dispositivo originale, e su cui, pertanto, si sarebbe 
dovuta basare la nuova versione, è la PCR Real-time con intercalante e analisi 
delle Curve di Melting. I primer utilizzati nella mix del prodotto originale sono i 
primer GP5+/GP6+. Si tratta di primer consensus che permettono di amplificare la 
maggior parte dei genotipi (o “tipi”) di HPV in aggregato. La sensibilità analit ica 
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di un sistema basato su questi primer non è omogenea rispetto ai diversi tipi di 
HPV identificabili e, per alcuni di essi, è inferiore a quanto richiesto dal WHO. 
Per prima cosa, si è stabilito di aggiungere altri primer alla coppia originale. In 
conseguenza di ciò, si è reso necessario l’impiego di reagenti idonei ad una 
reazione con molteplici primer ed, alla fine, l’intero assetto del saggio è stato 
modificato. Con l’occasione si è deciso di modificare un altro aspetto del saggio 
ed amplificare in multiplex, invece che in due reazioni distinte, il target patogeno 
ed il controllo interno. Lo scopo di ottenere un più alto livello di sensibilità 
analitica è stato raggiunto. Tuttavia, nel corso della pre-validazione del nuovo 
prototipo, sono emerse delle problematiche relative allo sviluppo di dimeri di 
primer che rischiavano di compromettere la corretta interpretazione dei risultati e 
che hanno portato alla sospensione del progetto. 
 
Nella seconda parte del mio dottorato ho lavorato alla progettazione, allo sviluppo 
e alla validazione di altri due dispositivi per la rilevazione dell’HPV, basati, 
questa volta, su PCR Real-time con primer genotipo-specifici e sonde di tipo 
TaqMan.  
I genotipi di HPV rilevati dal primo dei due saggi sono i 14 genotipi ad alto 
rischio più diffusi ovvero HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 e 
68. Il secondo saggio rileva invece la presenza dei due HPV a basso rischio più 
diffusi, HPV 6 e 11, e di altri HPV a possibile alto rischio, ovvero HPV 26, 53, 
67, 70, 73 e 82.  
Il primo saggio è già stato validato e le sue performance rientrano 
abbondantemente nei parametri stabiliti dal WHO e dal piano di validazione 
redatto in azienda. Tale saggio risulta, quindi, pronto per essere commercializzato 
come dispositivo per la detection degli HPV ad alto rischio con il nome 
REALQUALITY RQ-HPV HR MULTIPLEX. 
La validazione del secondo saggio è in corso, ma i primi dati sono promettenti. Il 
secondo saggio, se associato al primo, permette di offrire un pannello di indagine 
dell’HPV estremamente completo. Accanto al prodotto corrispondente al primo 
saggio, ne verrà, pertanto, proposto un secondo, corrispondente ai due saggi 
associati. Tale prodotto prenderà il nome di REALQUALITY RQ-HPV HR/LR 
MULTIPLEX. 
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